

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Sino Longitudinal Study on Cognitive Decline (SILCODE): study design of a longitudinal observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028188
Article Type:	Protocol
Date Submitted by the Author:	26-Nov-2018
Complete List of Authors:	Li, Xuanyu; XuanWu Hospital of Capital Medical University, Neurology wang, Xiaoni; XuanWu Hospital of Capital Medical University, , Neurology Su, Li; University of Cambridge, Psychiatry; Southwest University, Faculty of Psychology, Sino-Britain Centre for Cognition and Ageing Research Hu, Xiaochen; University of Cologne, Medical Faculty, Department of Psychiatry and Psychotherapy Han, Ying; XuanWu Hospital of Capital Medical University, Neurology; Beijing Institute for Brain Disorders, Center of Alzheimer's Disease
Keywords:	Dementia < NEUROLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, Nuclear radiology < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

Title Page:**Sino Longitudinal Study on Cognitive Decline (SILCODE): study design of a longitudinal observational study**

Xuanyu Li^{1#}, Xiaoni Wang^{1#}, Li Su^{2,3}, Xiaochen Hu⁴, Ying Han^{1,5,6,7*}

1. Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, China, 100053
2. Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, CB2 1TN
3. Sino-Britain Centre for Cognition and Ageing Research, Faculty of Psychology, Southwest University, Chongqing, China, 400715
4. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany, 50937
5. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China, 100053
6. Beijing Institute of Geriatrics, Beijing, China, 100053
7. National Clinical Research Center for Geriatric Disorders, Beijing, China, 100053

#These authors contributed equally to this work

*Corresponding Author: Ying Han, E-mail: hanying@xwh.ccmu.edu.cn, Tel: 13621011941

Keywords: Alzheimer's disease; subjective cognitive decline; magnetic resonance imaging; positron emission tomography; Conversion

Word count: 2990

ABSTRACT

Introduction Understanding the biological mechanism of subjective cognitive decline (SCD) in preclinical Alzheimer's disease (AD) and identifying those who will convert to mild cognitive impairment (MCI) in short time are critical for developing appropriate strategies for early diagnosis and intervention of AD. We aim to present the study protocol of Sino Longitudinal Study on Cognitive Decline (SILCODE), a longitudinal observational study focusing on SCD in the context of AD.

Methods and analysis Within SILCODE, participants will undergo extensive assessment, including clinical and neuropsychological assessments, blood and urine sample collection, glucose metabolism and amyloid positron emission tomography as well as multimodal MRI scans, with each subject followed up every 15-months for five years. The primary outcome measure is clinical progression.

Ethics and dissemination The medical research ethics committee and institutional review board of the XuanWu Hospital of Capital Medical University approved this study protocol (ID: [2017]046). The results will be published in peer-reviewed journals and presented at national and international scientific meetings.

Trial registration NCT03370744; pre-results.

Article Summary

Strengths and limitations of this study

- This is the first study to establish models predicting SCD conversion with different combination in China, which will provide references for clinical applications of SCD.
- This longitudinal study will use multi-modal MRI to investigate the brain structural and functional progressing pattern from SCD to MCI and explore the underlying mechanism.
- Besides neuropsychological and clinical information, blood and urine biomarker, multi-modal MRI, glucose metabolism and amyloid positron emission tomography will be used in this study.
- The study results will be limited by the participant's age (older than 55 years old) and study setting (not communicate based, participants from advertisement or referrals).

INTRODUCTION

Alzheimer's disease (AD) is the most common neurodegenerative disease and one of the greatest healthcare challenges of the 21st century.¹ It has been revealed that pathophysiology starts many years before the diagnosis of AD. Several recent clinical trials of A β -lowering therapies in the mild or moderate dementia stage have failed, which further encouraged researchers to shift their focus to the preclinical stage of AD.²

Subjective cognitive decline (SCD) refers to self-perceived cognitive decline relative to a previously normal status, without impaired performance on standardized neuropsychological tests.^{3,4} Evidence from recent research suggests that SCD may be one of the first symptomatic manifestation of AD.^{3,5} Previous studies have found higher rate and shorter time of conversion to mild cognitive impairment (MCI) and dementia in SCD individuals as compared to cognitively normal controls (NC).⁶ Further, the number of individuals with SCD presenting to the healthcare system (e.g. memory clinics) is increasing. So, persons with SCD are ideal for early diagnosis and intervention trails.

However, the heterogeneous nature of SCD limited its value in clinical application and SCD with different features presented different conversion rates. AD is characterized by the aggregation of β -amyloid (A β) deposition and studies have found higher A β in SCD predicting rapid cognitive decline.^{7,8} As to neuroimaging, thinner cortex in temporal, frontal and occipital areas is associated with steeper decline in cognition.^{9,10} Besides, neuropsychologic tests such as long-term verbal memory and life style may also have impact on SCD progression.¹¹ In aspect of SCD reports, studies found that fulfilling SCD-plus¹², reporting stable worries about cognitive decline^{13,14} and older at onset of symptoms¹⁵ showed higher risk progressing to MCI and dementia. Though studies have focused on features that could predict conversion in SCD, there are little research building predicting models from multi dimensions. And some noninvasive and convenient biomarkers of AD have not been identified in SCD individuals such as plasma A β and urine AD7c-NTP.

The Alliance for preclinical AD of China, belonging to the National Clinical Research Center for Geriatric Disorders, is a national multicenter research platform dedicated to development of clinical, neuroimaging, genetic, and biochemical biomarkers for the early detection and tracking of AD. Its sites include more than 180 hospital/research institute members all over

1
2
3
4 China. The alliance is led by professor Han and focuses on early diagnose of SCD due to
5 preclinical AD, which also develops and provides standard operation procedures and quality
6 control for harmonized data and material acquisition and storage across all sites.
7
8

9 Sino Longitudinal Study on Cognitive Decline (SILCODE) is a longitudinal observational
10 study based on the multicenter research platform of the Alliance for preclinical AD of China,
11 focusing on SCD in the context of AD. The main aims of SILCODE are: 1) establishing models
12 for predicting cognitive decline/conversion in SCD individuals. Furthermore, we would like to
13 build models based on various combinations of information since not all hospitals in China are
14 able to acquire PET data and some are even not able to acquire multi-modal MRI; 2) revealing
15 brain structural and functional progressing pattern in SCD individuals and exploring underlying
16 mechanism based on multi-modal neuroimaging. Herein, we report the study design of
17 SILCODE.
18
19
20
21
22
23
24
25
26
27

28 **METHODS**

29 **Overall study design**

30 This is an observational longitudinal study in China recruiting SCD. Participants are
31 consecutively recruited from standardized public advertisement, referrals from general
32 physicians or memory clinic or informants. During the baseline period, all participants will
33 receive clinical and neuropsychological examinations, blood tests, urine tests and multi-modal
34 MRI including structural MRI, diffusion tensor imaging (DTI) and functional MRI (fMRI).
35 Glucose metabolism and amyloid positron emission tomography (PET) are optional based on
36 individual's agreement. The follow-up scheme is every 15 months and the follow-up time is at
37 least 5 years for every individual. In the follow-up period, all evaluations are the same as the
38 baseline except for the amyloid PET. At each follow-up visit, diagnoses are reevaluated under
39 supervision of a neurologist. The figure 1 provides the overall study outline.
40
41
42
43
44
45
46
47
48
49
50
51

52 **Sample size**

53 This project will use sub-distribution hazard function model, one kind of competing risk model,
54 with nearly 50 independent variables before screening. After screening, we plan to choose at
55 most the top 10 variables for each model. So, appropriately 100 (10 time more than independent
56
57
58
59
60

variables) SCD-convertors are needed in our project. According to a previous meta-analysis,¹⁶ the annual conversion rate to MCI in SCD is 6.6% and the rate of follow up is about 90%. Finally, about 340 individuals with SCD are needed at baseline.

Inclusion/exclusion criteria

All eligible subjects are right-handed (the Edinburgh handedness scale score >40 points), older than 55 years old, and Han Chinese subjects. Written informed consent will be acquired from each subject before enrollment.

The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI. MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi.¹⁷ Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥ 9 . The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging–Alzheimer’s Association workgroups (NIA-AA)¹⁸ with a total CDR score of 1.

Exclusion criteria for all participants are: (1) history of stroke; (2) severe depression (Hamilton Depression Rating Scale score > 24); (3) other neurological conditions which could cause cognitive decline (e.g., brain tumors, Parkinson’s disease, encephalitis, or epilepsy) rather than AD spectrum disorders; (4) other diseases which could cause cognitive decline (e.g., thyroid dysfunction, severe anemia, syphilis, or HIV); (5) history of psychosis or congenital mental growth retardation; (6) cognitive decline caused by traumatic brain injury; (7) those who could not complete the study protocol or with contraindications for MRI.

Clinical, risk factor and neuropsychological assessments

1
2
3
4 The clinical assessments include a structured medical history, family history, physical
5 examination, routine laboratory tests (e.g. blood routine test, biochemical test, thyroid function
6 test, Vitamin B12, folic acid, treponema pallidum specific antibody and aids antibody) and MRI
7 (T1 and Flair) for medial temporal atrophy scale and Fazekas score.
8
9

10
11 For risk factors of AD, all subjects and their informants provide the following information:
12 vascular risk factors, occupation/retirement, socioeconomic status, nicotine and alcohol uses.
13 Additionally, Pittsburgh sleep quality index (PSQI),¹⁹ Rapid Eye Movement (REM) sleep
14 Behavior Disorder Screening Questionnaire (RBDSQ)²⁰ and the Epworth Sleepiness Scale
15 (ESS)²¹ will be used for sleep quality assessment and the Semi-quantitative Food Frequency
16 Questionnaire (SFFQ) will be used for nutrition intakes assessment.
17
18

19
20 The neuropsychological tests are selected for comparability with other similar ongoing
21 studies (e.g., DELCODE).²² The cognitive testing will be performed by trained
22 neuropsychologists. The neuropsychological battery measure different cognitive domain
23 including episodic memory (Auditory Verbal Learning Test-HuaShan version [AVLT-H]),²³
24 language (Animal Fluency Test, 30-item Boston Naming Test²⁴) and speed/executive function
25 (Shape Trails Test Parts A and B).²⁵ Besides, the SILCODE will implement tests for global
26 cognition, daily life ability and neuropsychiatric assessment including the Mini Mental State
27 Examination (MMSE), the Montreal Cognitive Assessment-basic (MoCA-B),²⁶ the memory
28 and executive screening (MES),²⁷ the CDR, FAQ, the 15-item short form of the Geriatric
29 Depression Scale (GDS), the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale
30 (HAMD) and the Neuropsychiatric Inventory (NPI).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Assessments of subjective cognitive functioning**

48 A semi-structured interview used by the DELCODE study is employed in this project to
49 evaluate the details of SCD.²² It includes information about the onset time, concerns,
50 comparison with others and so on in not only memory domain but also language, attention and
51 execute capacity. We also will require informant reports in evaluation of the self-reported
52 information as suggested by previous studies.⁴ In early stages of cognitive decline, self-report
53 may provide more information whereas in later stages of SCD, informant-report may be more
54 effective.⁵
55
56
57
58
59
60

1
2
3
4 For quantitative assessment of SCD, we will use a newly developed SCD questionnaire
5 including nine reliable SCD items, which are characterized by different domains, such as global
6 memory functioning and daily activities ability.²⁸ In addition, the 12-item Everyday Cognition
7 questionnaire will also be applied to all participants to measure SCD severity.
8
9
10
11
12

13 **Blood tests**

14 APOE genotype

15
16
17 SNPs rs7412 and rs429358 form the APOE $\epsilon 2/\epsilon 3/\epsilon 4$ haplotype. APOE will be genotyped
18 using the standard Sanger sequencing method (Sangon, Shanghai, China) using the following
19 primers: 5'-ACGCGGGCACGGCTGTCCAAGG-3' (forward) and 5'-
20 GGCGCTCGCGGATGGCGCTGA-3' (reverse). APOE will be amplified using the following
21 conditions: 1 cycle of 98 °C for 10 s, 35 cycles of 72 °C for 5 s, 1 cycle of 72 °C for 5 min.
22 PCR was performed in a final volume of 30 μ l, containing 10 pmol of forward and reverse
23 primers and 50 ng of genomic DNA template, using PrimeSTAR HS DNA Polymerase with
24 GC Buffer (Takara Bio).
25
26
27
28
29
30
31
32
33
34

35 Plasma β -amyloid

36
37 Recently, some research found that plasma amyloid level was correlated with cognitive
38 capacity and cerebrospinal fluid amyloid protein.^{29, 30} Especially, when predicting brain
39 amyloid deposition, the accuracy of the composite biomarker (amyloid- β precursor protein 669-
40 711/ A β 1-42 and A β 1-40/A β 1-42 ratios) could approximately equal to 90%.³¹ So, we would
41 like to identify if the plasma β -amyloid is also associated with cognitive decline in SCD
42 individuals. Plasma A β will be determined using commercially available kit, V-PLEX A β
43 Peptide Panel 1 (6E10) Kit (K15200E) (Mesoscale Diagnostics LLC, Rockville,
44 USA). A β peptide levels from each blood draw will be measured in duplicate using the same
45 aliquot.
46
47
48
49
50
51
52
53
54
55

56 **Urine tests**

57
58 Ten ml of first morning urine will be collected from each subject and then immediately
59 refrigerated. An enzyme-linked immunosorbent assay kit will be used to detect the protein level
60

of AD7c-NTP in the urine specimens.

Imaging protocol

MRI data will be acquired using an integrated simultaneous 3.0 Tesla TOF PET/MR (SIGNA PET/MR, GE Healthcare, Milwaukee, WI, USA) at the XuanWu Hospital of Capital Medical University. For each participant, simultaneous PET and 3.0 T MRI data will be obtained. Brain MR images will be inspected by an experienced neuroradiologist (with more than 5 years' experience).

Positron emission tomography: All participants will be invited for optional [¹⁸F] florbetapir (AV-45) and [¹⁸F] fluorodesoxyglucose (FDG) in 3-dimensional acquisition mode with interval between 3-90 days. For FDG-PET, each subject will be instructed to fast for at least 6 h and has a confirmed serum glucose level below 8 mmol/L; 35 minutes dynamic scan is acquired about 40 minutes after an intravenous injection of 3.7 MBq/kg of 18F-FDG. For Aβ-PET, 35 minutes dynamic scan is acquired about 40 minutes after an intravenous injection of 7-10mCi [¹⁸F] florbetapir. The PET data are acquired using a TOF-OSEM algorithm (time-of-flight ordered subset expectation maximization) with the following parameters: 8 iterations, 32 subsets matrix = 192×192, field of view (FOV)= 350×350, half-width height = 3.

Structural MRI: Parameters for T1-weighted 3D brain structural images are as following: SPGR sequence, FOV=256×256 mm², matrix=256×256, slice thickness=1 mm, gap=0, slice number=192, repetition time (TR) =6.9 ms, echo time (TE)=2.98 ms, inversion time (TI)=450 ms, flip angle =12°, voxel size = 1×1×1 mm³.

DTI: DTI data are obtained with Single-shot spin-echo diffusion-weighted EPI sequence with following parameters: FOV=224×224mm², data matrix=112×112, slice thickness=2mm, gap=0, slice number=70, slice order=interleaved, TR=16500 ms, TE=95.6 ms, 30 gradient directions and 5 b0 images (b=1000s/mm²), voxel size =2×2×2 mm³.

Resting state fMRI: Single-shot gradient-echo EPI sequence is used for rs-fMRI with following parameters: FOV=224×224mm², data matrix=64×64, slice thickness=4.0 mm, gap=1.0 mm, slice number=28, slice order=interleaved, TR=2000ms, TE=30 ms, FA=90°, voxel size =3.5×3.5×4 mm³.

Task based fMRI: We will also conduct an optional block design fMRI paradigm to measure

1
2
3
4 somatosensory mismatch negativity (MMN), which could be elicited by discriminable change
5 in the acoustic environment. The specific cognitive function links to three stages including
6 sensory register, short-term memory and long-term memory. Whereas most studies were
7 concentrated on short-term and long-term memory, few studies focus on somatosensory MMN.
8 So, this project will use a self-designed air jet pressure stimulation device combined with fMRI
9 to test the somatosensory MMN. For the MMN condition, the switch trial stimuli are a 'deviant'
10 and has proven to elicits robust MMNs. For the matched control condition, the same two stimuli
11 were alternated sequentially to form a regular pattern, such that no MMN would be elicited.
12
13
14
15
16
17
18
19
20

21 **Imaging data analysis**

22
23 For analysis of the structural MRI, morphological features like regional cortical thickness and
24 gray matter volume will be analyzed based on the T1 weighted images. DTI data will be
25 analyzed by tract-based spatial statistics (TBSS) regarding the fractional anisotropy (FA), mean
26 diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AxD). Resting-state functional
27 MRI data will be analyzed by several different strategies including the amplitude of low-
28 frequency fluctuations (ALFF), regional homogeneity (ReHo), and functional connectivity
29 derived from the independent component analysis (ICA). Further, structural, white matter and
30 functional network will be constructed and topographic characteristic such as modality, rich-
31 club will be calculated.
32
33
34
35
36
37
38
39

40
41 Analysis of PET data will be performed based on standardized uptake volume ratios (SUVR)
42 with pre-specified cut-offs. In addition, voxel-based and ROI-based methods will be used in
43 both FDG-PET and A β -PET.
44
45
46
47

48 **Statistical analysis**

49
50 All data (demographic information, clinical data, risk factors, neuropsychologic tests, blood
51 and urine biomarker, multi-modal MRI biomarker, glucose mentalism and amyloid deposition)
52 will be compared between SCD convertors and SCD non-convertors with two sample t-test for
53 continuous variables and chi-square test for categorical variables.
54
55
56
57

58 Four models will be established in this project. Model 1 will simply take demographic data,
59 lifestyle, clinical assessment, neuropsychological assessments and SCD report into account.
60

Model 2 will add APOE genotype, plasma A β and urine AD7c-NTP on the basis of model 1. Model 3 will take neuroimaging data into account on the basis of model 2 and model 4 will include amyloid-PET and FDG-PET on the basis of model 3. Detailed descriptions of independent variables are provided in table 1. The primary outcome is defined as converting to MCI.

Table 1 independent variable list

Demographic data	age; education level; family history of dementia; socioeconomic information
Lifestyle	nicotine and alcohol use; sleep quality (PSQI, RBDSQ, ESS); nutrition style
Clinical assessment	vascular risk factors (hypertension, hyperlipemia, diabetes, coronary heart disease, Fazekas score); medial temporal lobe atrophy scale; HAMA; HAMD; GDS
Neuropsychological assessment	AVLT-D; AVLT-R; STT-A; STT-B; BNT; AFT
SCD report	onset time; comparison with others; SCD-Q9; Ecog; consistency of SCD; inform report
Blood tests	APOE genotype; Plasma β -amyloid
Urine tests	level of AD7c-NTP
Neuroimage data	cortical thickness; gray matter volume; FA; MD; RD; AxD; ALFF; ReHo; functional connectivity; network characteristic (rich-club, modality)
PET data	global SUVR of FDG-PET and A β -PET

HAMA, the Hamilton Anxiety Scale; HAMD, the Hamilton Depression Scale; GDS, Geriatric Depression Scale; AVLT, Auditory Verbal Learning Test; STT, Shape Trails Test; BNT, Boston naming test; AFT, animal fluency test; SCD, subjective cognitive decline; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; AxD, axial diffusivity; ALFF, amplitude of low-frequency fluctuations; ReHo: regional homogeneity; SUVR, standardized uptake volume ratios

The least absolute shrinkage and selection operator (LASSO) logistic regression model with

1
2
3
4 penalty parameter tuning will be used for variable screening. Then, using the sub-distribution
5 hazard function model, we will analyze the effect of variables screening by LASSO on the time
6 to conversion to MCI in five-years follow-up. The hazard ratio (HRs) with 95% confidence
7 intervals are determined. All statistical tests were performed using R statistical software. The
8 "glmnet" package will be used for the LASSO logistic regression model analysis and the
9 "cmprsk" package will be performed for sub-distribution hazard function model.
10
11
12
13
14

15 To revealing progressing structural and functional pattern in SCD, one-way analysis of
16 variance (ANOVA) will be used in those who convert to MCI and AD dementia in five years
17 with Bonferroni for post-hoc test. The structural parameters (global and regional gray matter
18 volume, cerebral cortex thickness), white matter parameters (regional FA, MD, RD, AxD),
19 functional characteristic (global and regional ALFF, ReHo, functional connectivity) and
20 network characteristics will be compared in this part.
21
22
23
24
25
26
27
28

29 DISCUSSION

30
31 The current study evaluates characteristics of SCD those presenting cognitive decline within
32 five years and furthermore we will construct risk forecast models based on different
33 combination of potential predictors to achieve clinical practice of SCD.
34
35

36
37 Considering the long preclinical stage of AD and compensated cognitive function in SCD
38 stage, the application of a refined SCD approach as an enrichment strategy for clinical trials
39 focusing on preclinical AD shows great promise. The SILCODE is a longitudinal study and we
40 will focus on features of SCD converters with multi-perspective analysis. Especially, we would
41 like to establish an integrated diagnostic system for early detection and prediction of SCD
42 progressing at the individual level. We aim to provide scientific evidence for more effective
43 diagnosis of SCD due to AD and explore the underlying mechanism of SCD.
44
45
46
47
48
49

50
51 In this project, plasma A β , urine AD7c-NTP and multi-modal MRI will also be included in
52 the predicting models. These examinations are non-invasive and feasible in clinical practice.
53 Previous studies have found their diagnostic efficiency in MCI and dementia,^{31, 32} but in SCD
54 individuals, there are few evidences. So, this project also focuses these new biomarkers and try
55 to identify their usage in clinical scene. Additionally, through this project, we would like to
56 reveal the structural and functional patterns of involved brain area, especially the temporal and
57
58
59
60

1
2
3
4 spatial sequences, which may provide basis for us to understand the relationship between
5 structural and functional changes during disease progression.
6

7
8 At last, cultural factors may impact on SCD relate to language, social stigmatization of
9 cognitive problems, styles of responding on self-reported measures, tolerance of slowly
10 progressive cognitive decline in aging and others,³³ which indicating the need for SCD research
11 in China. SILCODE is a longitudinal study in China and the implement of SILCODE would
12 provide characteristics of SCD in China, which contribute to the harmonization of the SCD
13 concept across cultural borders.
14
15
16
17
18

21 **Author Contributions**

22
23 Xuanyu Li and Xiaoni Wang are joint first authors. All authors contributed to the overall design
24 and implementation of the study. Xuanyu Li and Xiaoni Wang drafted the manuscript. Ying
25 Han is supervising the project and made critical revision of the manuscript for important
26 intellectual content. All authors contributed to the drafting of the manuscript and approved the
27 final manuscript.
28
29
30
31
32

35 **Funding**

36
37 This work was supported by The National Key Research and Development Program of China
38 (2016YFC1306300), National Natural Science Foundation of China (Grant 61633018,
39 81801052, 81430037, 81471731, 31371007), Beijing Nature Science Foundation (7132147),
40 Beijing Municipal Commission of Health and Family Planning (PXM2018_026283_000002),
41 Alzheimer's Research UK (ARUK-SRF2017B-1), Addenbrooke's Charitable Trust,
42 Alzheimer's Society and The Lewy Body Society.
43
44
45
46
47
48
49

50 **Competing interests**

51
52 None declared.
53
54
55

56 **Patient consent**

57
58 All participation is based on written informed consent and the participants will be able to
59 withdraw from the study at any time.
60

Ethics approval

Ethical approval of this has been obtained from the medical research ethics committee and institutional review board of the XuanWu Hospital, Capital Medical University (ID: [2017]046).


REFERENCES

1. Scheltens P, Blennow K, Breteler MM, *et al.* Alzheimer's disease. *Lancet* 2016;388(10043):505-17.
2. Dubois B, Hampel H, Feldman HH, *et al.* Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* 2016;12(3):292-323.
3. Jessen F, Amariglio RE, van Boxtel M, *et al.* A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement* 2014;10(6):844-852.
4. Molinuevo JL, Rabin LA, Amariglio R, *et al.* Implementation of subjective cognitive decline criteria in research studies. *Alzheimers Dement* 2017;13(3):296-311.
5. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. *Annu Rev Clin Psychol* 2017;13:369-396.
6. Reisberg B, Shulman MB, Torossian C, *et al.* Outcome over seven years of healthy adults with and without subjective cognitive impairment. *Alzheimers Dement* 2010;6(1):11-24.
7. Amariglio RE, Buckley RF, Mormino EC, *et al.* Amyloid-associated increases in longitudinal report of subjective cognitive complaints. *Alzheimers Dement (N Y)* 2018;4:444-449.
8. Vogel JW, Varga DM, La Joie R, *et al.* Subjective cognitive decline and beta-amyloid burden predict cognitive change in healthy elderly. *Neurology* 2017;89(19):2002-2009.
9. Schultz SA, Oh JM, Kosciak RL, *et al.* Subjective memory complaints, cortical thinning, and cognitive dysfunction in middle-aged adults at risk for AD. *Alzheimers Dement (Amst)* 2015;1(1):33-40.
10. Verfaillie S, Slot RE, Tijms BM, *et al.* Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. *Neurobiol Aging* 2018;61:238-244.
11. Bessi V, Mazzeo S, Padiglioni S, *et al.* From Subjective Cognitive Decline to Alzheimer's Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study. *J Alzheimers Dis* 2018;63(4):1523-1535.
12. Fernandez-Blazquez MA, Avila-Villanueva M, Maestu F, *et al.* Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. *J Alzheimers Dis* 2016;52(1):271-81.
13. Roehr S, Villringer A, Angermeyer MC, *et al.* Outcomes of stable and unstable patterns of subjective cognitive decline - results from the Leipzig Longitudinal Study of the Aged (LEILA75+). *BMC Geriatr* 2016;16(1):180.
14. Wolfsgruber S, Kleineidam L, Wagner M, *et al.* Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. *J Alzheimers Dis* 2016;54(3):1135-1146.
15. Fonseca JA, Ducksbury R, Rodda J, *et al.* Factors that predict cognitive decline in patients with subjective cognitive impairment. *Int Psychogeriatr* 2015;27(10):1671-7.
16. Mitchell AJ, Beaumont H, Ferguson D, *et al.* Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. *Acta Psychiatr Scand* 2014;130(6):439-

- 1
2
3 51.
4
5 17. Bondi MW, Edmonds EC, Jak AJ, *et al.* Neuropsychological criteria for mild cognitive impairment
6 improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis*
7 2014;42(1):275-89.
8
9 18. McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to Alzheimer's
10 disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups
11 on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7(3):263-269.
12
13 19. Buysse DJ, Reynolds CR, Monk TH, *et al.* The Pittsburgh Sleep Quality Index: a new instrument
14 for psychiatric practice and research. *Psychiatry Res* 1989;28(2):193-213.
15
16 20. Nomura T, Inoue Y, Kagimura T, *et al.* Utility of the REM sleep behavior disorder screening
17 questionnaire (RBDSQ) in Parkinson's disease patients. *Sleep Med* 2011;12(7):711-3.
18
19 21. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*
20 1991;14(6):540-5.
21
22 22. Jessen F, Spottke A, Boecker *et al.* Design and first baseline data of the DZNE multicenter
23 observational study on pre-dementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*
24 2018;7;10(1):15.
25
26 23. Zhao Q, Guo Q, Liang X, *et al.* Auditory Verbal Learning Test is Superior to Rey-Osterrieth
27 Complex Figure Memory for Predicting Mild Cognitive Impairment to Alzheimer's Disease. *Curr*
28 *Alzheimer Res* 2015;12(6):520-6.
29
30 24. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. 2nd ed. Philadelphia: Lea
31 &Febiger,1983.
32
33 25. Zhao Q, Guo Q, Li F, *et al.* The Shape Trail Test: application of a new variant of the Trail making
34 test. *PLoS One* 2013;8(2):e57333.
35
36 26. Chen KL, Xu Y, Chu AQ, *et al.* Validation of the Chinese Version of Montreal Cognitive
37 Assessment Basic for Screening Mild Cognitive Impairment. *J Am Geriatr Soc* 2016;64(12):e285-e290.
38
39 27. Guo QH, Zhou B, Zhao QH, *et al.* Memory and Executive Screening (MES): a brief cognitive test
40 for detecting mild cognitive impairment. *BMC Neurol* 2012;12:119.
41
42 28. Hao L, Wang XN, Zhang L, *et al.* Prevalence, Risk Factors, and Complaints Screening Tool
43 Exploration of Subjective Cognitive Decline in a Large Cohort of the Chinese Population. *J Alzheimers*
44 *Dis* 2017;60(2):371-388.
45
46 29. Llado-Saz S, Atienza M, Cantero JL. Increased levels of plasma amyloid-beta are related to cortical
47 thinning and cognitive decline in cognitively normal elderly subjects. *Neurobiol Aging*
48 2015;36(10):2791-7.
49
50 30. Hanon O, Vidal JS, Lehmann S, *et al.* Plasma amyloid levels within the Alzheimer's process and
51 correlations with central biomarkers. *Alzheimers Dement* 2018;14(7):858-868.
52
53 31. Nakamura A, Kaneko N, Villemagne VL, *et al.* High performance plasma amyloid-beta biomarkers
54 for Alzheimer's disease. *Nature* 2018;554(7691):249-254.
55
56 32. Zhang J, Zhang CH, Li RJ, *et al.* Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's
57 disease: a systematic review and meta-analysis. *J Alzheimers Dis* 2014;40(1):153-9.
58
59 33. Wu Q. Subjective cognitive impairment of older adults: a comparison between the US and China.
60 *Int J Methods Psychiatr Res* 2016;25(1):68-75.

1
2
3
4
5
6
7
8
9
10 **Figure legend**

11 Figure 1 Flow chart of SILCODE. SCD, subjective cognitive decline; sMRI, structural MRI;
12
13 DTI, diffusion tensor imaging; fMRI, functional MRI; FDG-PET, fluorodesoxyglucose positron
14 emission tomography; A β -PET, β -amyloid positron emission tomography
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



45
46
47
48
49

Figure 1 Flow chart of SILCODE

317x458mm (96 x 96 DPI)

BMJ Open

**Sino Longitudinal Study on Cognitive Decline (SILCODE):
protocol for a Chinese longitudinal observational study to
develop risk prediction models of conversion to mild
cognitive impairment in individuals with subjective
cognitive decline**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028188.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Mar-2019
Complete List of Authors:	Li, Xuanyu; XuanWu Hospital of Capital Medical University, Neurology wang, Xiaoni; XuanWu Hospital of Capital Medical University, , Neurology Su, Li; University of Cambridge, Psychiatry; Southwest University, Faculty of Psychology, Sino-Britain Centre for Cognition and Ageing Research Hu, Xiaochen; University of Cologne, Medical Faculty, Department of Psychiatry and Psychotherapy Han, Ying; XuanWu Hospital of Capital Medical University, Neurology; Beijing Institute for Brain Disorders, Center of Alzheimer's Disease
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Neurology
Keywords:	Dementia < NEUROLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, Nuclear radiology < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

Title Page:**Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline**

Xuanyu Li^{1#}, Xiaoni Wang^{1#}, Li Su^{2,3}, Xiaochen Hu⁴, Ying Han^{1,5,6,7*}

1. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China, 100053
2. Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, CB2 1TN
3. Sino-Britain Centre for Cognition and Ageing Research, Faculty of Psychology, Southwest University, Chongqing, China, 400715
4. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany, 50937
5. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China, 100053
6. Beijing Institute of Geriatrics, Beijing, China, 100053
7. National Clinical Research Center for Geriatric Disorders, Beijing, China, 100053

#These authors contributed equally to this work

*Corresponding Author: Ying Han, E-mail: hanying@xwh.ccmu.edu.cn, Tel: 13621011941

Keywords: Alzheimer's disease; subjective cognitive decline; magnetic resonance imaging; positron emission tomography; conversion

Word count: 5421

ABSTRACT

Introduction Understanding the biological mechanism of subjective cognitive decline (SCD) in preclinical Alzheimer's disease (AD) and identifying those who will convert to mild cognitive impairment (MCI) in a short time are critical for developing appropriate strategies for early diagnosis and intervention of AD. We aim to present the study protocol of the Sino Longitudinal Study on Cognitive Decline (SILCODE), a longitudinal observational study focusing on SCD in the context of AD.

Methods and analysis Within SILCODE, approximately 800 subjects between the ages of 50-79 years old with SCD will be recruited from standardized public advertisement or memory clinics. They will undergo extensive assessment, including clinical and neuropsychological assessments, blood samples collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, multimodal MRI scans (structural MRI, diffusion tensor imaging, resting-state functional MRI and optional task-based functional MRI) as well as optional glucose metabolism and amyloid positron emission tomography. Subjects will be contacted by telephone every 3 months and be interviewed average every 15 months for five years. The study endpoint is the development of mild cognitive impairment or dementia. Jak & Bondi's actuarial neuropsychological method will be used for diagnosis of MCI. The least absolute shrinkage and selection operator (LASSO) logistic regression model followed by the sub-distribution hazard function model with death as a competing risk will be constructed to establish risk prediction models.

Ethics and dissemination The medical research ethics committee and institutional review board of the Xuanwu Hospital of Capital Medical University approved this study protocol (ID: [2017]046). The results will be published in peer-reviewed journals and presented at national and international scientific conferences.

Trial registration NCT03370744; pre-results.

Article Summary

Strengths and limitations of this study

- A strength of this study is the use of multiple markers (clinical, blood, urine and imaging markers) to establish models predicting SCD conversion to MCI, which will provide

1
2
3
4 references for clinical applications of SCD.

- 5 ● This longitudinal study could enrich the understanding of SCD based on a large-scale
6 Chinese population, since cultural factors have an impact on SCD.
- 7
8 ● The relatively short follow-up duration (5 years) of this study makes longitudinal data will
9 be only analyzed in an exploratory way.
- 10
11 ● The study results will be limited by the research environment that individuals will be
12 recruited from memory clinics and volunteer samples without community-based samples
13 or population-based samples.
14
15
16
17
18
19

20 INTRODUCTION

21 Alzheimer's disease (AD) is the most common neurodegenerative disease and one of the
22 greatest healthcare challenges of the 21st century.¹ It has been revealed that pathophysiology
23 starts many years before the onset of clinical symptoms.² Several recent clinical trials of A β -
24 lowering therapies in the mild or moderate dementia stage and even mild cognitive impairment
25 stage have failed,^{3 4} which further encouraged researchers to shift their focus to the preclinical
26 stage of AD for the target of new treatments.⁵
27
28
29
30
31
32

33 Subjective cognitive decline (SCD) refers to self-perceived cognitive decline relative to a
34 previously normal status, without impaired performance on standardized neuropsychological
35 tests.^{6 7} Evidences from recent researches suggest that SCD may be one of the earliest
36 symptomatic manifestations of AD.^{6 8} Previous studies have found higher rate and shorter time
37 of conversion to mild cognitive impairment (MCI) and dementia in SCD individuals as
38 compared to normal controls (NC).⁹⁻¹² SCD may be an early trigger for help-seeking¹³ and we
39 have observed that the number of individuals with SCD presenting to the healthcare system
40 (e.g. memory clinics) is increasing in our clinical practice as the rising awareness of AD
41 dementia in China. Individuals with SCD are ideal for ultra-early diagnosis and intervention
42 trials.
43
44
45
46
47
48
49
50
51

52 However, the heterogeneous nature of SCD limited its value in the clinical application.
53 Research to date has focused on factors for predicting risk for MCI/AD progression in SCD.¹⁴⁻¹⁷
54 Though some longitudinal and observational studies of SCD are ongoing,¹⁸⁻²⁰ there is a lack of
55 data from China even Asian. However, cultural factors impacting on SCD relate to language,
56
57
58
59
60

1
2
3
4 social stigmatization of cognitive problems, styles of responding on self-reported measures (e.g.
5 extremity of answers), tolerance of slowly progressive cognitive decline in aging and others.²¹
6 Association between objective cognitive performance and SCD is different across races.²² Our
7 group reported that the prevalence of SCD was 14.4% in the Shunyi District of Beijing, China,²³
8 which is different from prevalence of SCD reported in western countries.^{24 25} Thus there is a
9 need for more findings from longitudinal studies based on large-scale Chinese population.
10
11
12
13
14

15 The Alliance for preclinical AD in China, belonging to the National Clinical Research Center
16 for Geriatric Disorders, is a national multicenter research platform, which dedicates to the
17 development of clinical, neuroimaging, genetic, and biochemical biomarkers for the early
18 detection and tracking of AD. Its sites include more than 180 hospitals/research institutes
19 members all over China. The alliance is led by professor Han and focuses on the early detection
20 of SCD during preclinical AD, which also develops and provides standard operating procedures
21 and quality control for harmonized data and material acquisition and storage across all sites.
22
23
24
25
26
27
28

29 In this protocol, we introduce in detail the design of the Sino Longitudinal Study on
30 Cognitive Decline (SILCODE) study. This is an ongoing longitudinal observational study based
31 on the multicenter research platform of the Alliance for preclinical AD in China, focusing on
32 SCD in the context of AD. The main aim of SILCODE is to estimate cognitive decline and
33 establish statistical prediction models in SCD in Chinese elderly people.
34
35
36
37
38
39

40 **METHODS**

41 **Overall study design**

42 This is an observational longitudinal study in China recruiting SCD. During the baseline period,
43 all eligible subjects with SCD will be invited to receive clinical and neuropsychological
44 examinations, blood tests, urine tests and multi-modal MRI including structural MRI (sMRI),
45 diffusion tensor imaging (DTI) and resting-state functional MRI (rs-fMRI) sequentially as
46 shown in figure 1. Glucose metabolism and amyloid positron emission tomography (PET) and
47 task-based fMRI (t-fMRI) will be optional based on the individual's agreement. A semi-
48 structured interview¹⁸ as well as the SCD questionnaire²⁶ and Everyday Cognition questionnaire
49 (ECog)²⁷ will be used to assess the SCD. The duration between neuropsychological tests and
50 other data collection will be within three months. Subjects will be contacted by telephone every
51
52
53
54
55
56
57
58
59
60

1
2
3
4 3-months and be interviewed average every 15 months for five years (4 time points). the
5 Montreal Cognitive Assessment-basic (MoCA-B)²⁸ subtests (language, delayed recall and
6 orientation) will be taken during the call. Those expressing significantly cognitive decline on
7 the telephone will be interviewed ahead of time for the next follow-up. During the follow-up
8 visits with interview, evaluations including clinical and neuropsychological examinations,
9 blood tests, urine tests, and multi-modal MRI as well as optional glucose metabolism PET and
10 t-fMRI will be conducted average every 15 months. At each follow-up visit, diagnoses will be
11 reevaluated under the supervision of two neurologists. Figure 1 provides the overall study
12 outline.

23 **Patient and Public Involvement**

24 Patients and public will not be involved in the development of the research question or the
25 design of the study. Patients will not be involved in the recruitment and conduct of the study.
26 The general results will be disseminated to participants through public education activities.

33 **Sample size calculation**

34 The formula proposed by Hsieh and Lavori²⁹ was used to estimate the sample size in our study with
35 PASS software (version 15.0.5). According to a previous meta-analysis,⁹ the cumulative
36 conversion proportion was 24.4% over a mean of 4.1 years follow-up. We assumed the power
37 (1- β) was 80%, α was 0.05 and the rate of loss to follow-up was 20%. Due to the lack of
38 statistical data of SCD, we calculated the sample size with data reported by Licher et al³⁰ and
39 Pinto et al³¹ (Hazard ratio= 1.03, standard deviation=8.2, R^2 =0.127) from cognitively normal
40 elderly subjects for the association between age and cognitive decline. This calculation
41 rendered a total sample size of 762. Considering the internal validation, we will recruit at least
42 800 subjects.

54 **Recruitment of participants**

55 Participants will be consecutively recruited from standardized public advertisements, referrals
56 from general physicians or memory clinics or informants. Residents who meet the inclusion
57 criteria will be recruited. Written informed consent will be acquired from each subject before
58
59
60

enrollment.

SCD, MCI and dementia diagnostic criteria

SCD is defined by the research criteria for pre-MCI (SCD) proposed by Jessen et al in 2014⁶: (1) Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; (2) Normal age-, gender-, and education-adjusted performance on standardized cognitive tests.

MCI is defined by an actuarial neuropsychological method proposed by Jak and Bondi.³² Participants are considered to have MCI if any one of the following three criteria are met as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative means) on both measures within at least one cognitive domain (memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled (memory, language, or speed/executive function); (3) the Functional Activities Questionnaire (FAQ) ≥ 9 . The normative means in our study are from Guo and his team in a Chinese population.³³⁻³⁶ Measures and normative means are shown in table 1.

The diagnosis of AD dementia is based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition and the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging–Alzheimer’s Association workgroups (NIA-AA),³⁷ who have a total CDR score ≥ 1 .

Table 1 Cognitive domains, neuropsychological tests and normative means

Cognitive domains	Neuropsychological tests	Normative means
Memory	Auditory Verbal Learning Test- long delayed memory ³³	50-59 years old: 5; 60-69 years old: 4; 70-79 years old: 3
	Auditory Verbal Learning Test- recognition ³³	50-59 years old: 20; 60-69 years old: 19; 70-79 years old: 18
Language	Animal Fluency Test ³⁵	junior middle school: 12; high school: 13; college: 14
	30-item Boston Naming Test ³⁴	junior middle school: 20; high school: 21;

		college: 22
speed/executive	Shape Trails Test Parts A ³⁶	50-59 years old: 70s; 60-69 years old: 80s; 70-79 years old: 100s
	Shape Trails Test Parts B ³⁶	50-59 years old: 180s; 60-69 years old: 200s; 70-79 years old: 240s

Inclusion/exclusion criteria

The inclusion criteria are as follows: (1) older than 50 years old and Mandarin-speaking subjects; (2) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (3) concerns (worries) associated with memory complaint; and (4) failure to meet the criteria for MCI or dementia.

Exclusion criteria are as follows: (1) history of stroke; (2) current major psychiatric diagnoses such as severe depression and anxiety. When mild and moderate symptoms of psychiatric diagnosis are suspected, patients will not be excluded³⁸. They will be evaluated by a psychiatrist to clear if the psychiatric diagnoses are the cause of SCD; (3) other neurological conditions which could cause cognitive decline (e.g., brain tumors, Parkinson's disease, encephalitis, or epilepsy) rather than AD spectrum disorders; (4) other diseases which could cause cognitive decline (e.g., thyroid dysfunction, severe anemia, syphilis, or HIV); (5) history of psychosis or congenital mental growth retardation; (6) cognitive decline caused by traumatic brain injury; (7) those who could not complete the study protocol or with contraindications for MRI.

Clinical progression

At each follow-up visit, diagnoses will be reevaluated under the supervision of two neurologists. The main outcome measure of clinical progression in our study is converting to MCI or AD dementia. Time to event is the date difference between the baseline neuropsychological tests and the date at which the MCI is first diagnosed. For those who miss the diagnosis of MCI during follow-up, the time between the baseline neuropsychological tests and dementia first diagnosed is defined as the time to event in our study.

Assessments of subjective cognitive functioning

A semi-structured interview used by the DELCODE study will be employed in this project to evaluate the details of SCD.¹⁸ It includes information about the onset time, concerns, comparison with others, and the history of visiting a physician not only memory domain but also language, attention, and executive. We also will require informant reports in the evaluation of the self-reported information as suggested by Subjective Cognitive Decline Initiative Working Group.^{7 39}

For quantitative assessment of the severity of SCD, we will use a newly developed SCD questionnaire including nine reliable SCD items (table 2), which are characterized by different domains, such as global memory functioning and daily activities ability.^{23 26} In addition, the 12-item ECog²⁷ will also be applied to all participants to measure SCD severity. These questionnaires will not be considered as inclusion criteria but only for statistical analysis.

Table 2 items included in SCD questionnaire²⁶

Items
Do you think you have problems with your memory?
Do you have difficulty remembering a conversation from a few days ago?
Do you have complaints about your memory in the last 2 years?
How often is the following a problem for you: Personal dates
How often is the following a problem for you: Phone numbers you use frequently
On a whole, do you think that you have problems remembering things that you want to do or say?
How often is the following a problem for you: Going to the store and forgetting what you wanted to buy
Do you think that your memory is worse than 5 years ago?
Do you feel you are forgetting where things were placed?

Clinical, risk factor and neuropsychological assessments

The clinical assessments include a structured medical history, physical examination, routine laboratory tests (including blood routine test, biochemical test, thyroid function test, Vitamin B12, folic acid, treponema pallidum specific antibody and HIV antibody) and MRI (T1 and Flair) for medial temporal atrophy scale and Fazekas score.

1
2
3
4 For risk factors of AD, all subjects and their informants will provide the following
5 information: family history, vascular risk factors, occupation/retirement, socioeconomic status,
6 cigarettes, and alcohol uses, and nutrition style. Additionally, Pittsburgh sleep quality index
7 (PSQI)⁴⁰, Rapid Eye Movement (REM) sleep Behavior Disorder Screening Questionnaire
8 (RBDSQ)⁴¹ and the Epworth Sleepiness Scale (ESS)⁴² will be used for sleep quality assessment
9

10
11
12
13 The neuropsychological tests are selected for comparability with other similar ongoing
14 studies (e.g., DELCODE).¹⁸ To avoid deviations in the evaluation, the neuropsychologists
15 performing the cognitive tests will be trained with standard guidelines. Kappa coefficient
16 (Fleiss' kappa) will be used to measure the assessment agreement among the
17 neuropsychologists. Neuropsychological results will be double-checked. The
18 neuropsychological battery (table 1) measures different cognitive domains including episodic
19 memory (Auditory Verbal Learning Test-HuaShan version [AVLT-H]),³³ language (Animal
20 Fluency Test,³⁵ 30-item Boston Naming Test³⁴ and speed/executive function (Shape Trails Test
21 Parts A and B³⁶). Besides, the SILCODE will implement tests for global cognition, daily life
22 ability and neuropsychiatric assessment including MoCA-B,²⁸ the memory and executive
23 screening (MES),⁴³ the CDR, FAQ, the 15-item short form of the Geriatric Depression Scale
24 (GDS), the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale (HAMD) and
25 the Neuropsychiatric Inventory (NPI).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Blood tests**

42 ApoE genotype

43
44 SNPs rs7412 and rs429358 form the ApoE $\epsilon 2/\epsilon 3/\epsilon 4$ haplotype. ApoE will be genotyped
45 using the standard Sanger sequencing method (Sangon, Shanghai, China) using the following
46 primers: 5'-ACGCGGGCACGGCTGTCCAAGG-3' (forward) and 5'-
47 GGCGCTCGCGGATGGCGCTGA-3' (reverse). ApoE will be amplified using the following
48 conditions: 1 cycle of 98 °C for 10 s, 35 cycles of 72 °C for 5 s, 1 cycle of 72 °C for 5 min.
49 PCR was performed in a final volume of 30 μ l, containing 10 pmol of forward and reverse
50 primers and 50 ng of genomic DNA template, using PrimeSTAR HS DNA Polymerase with
51 GC Buffer (Takara Bio).
52
53
54
55
56
57
58
59
60

Plasma β -amyloid

Recently, some research found that plasma amyloid level was correlated with cognitive capacity and cerebrospinal fluid amyloid protein.^{44,45} Especially, when predicting brain amyloid deposition, the accuracy of the composite biomarker (amyloid- β precursor protein 669-711/ $A\beta$ 1-42 and $A\beta$ 1-40/ $A\beta$ 1-42 ratios) could approximately equal to 90%.⁴⁶ So, we would like to identify if the plasma β -amyloid is also associated with cognitive decline in SCD individuals. Plasma $A\beta$ will be determined using commercially available kit, V-PLEX $A\beta$ Peptide Panel 1 (6E10) Kit (K15200E) (Mesoscale Diagnostics LLC, Rockville, USA). $A\beta$ peptide levels from each blood draw will be measured in duplicate using the same aliquot.

Urine tests

Ten ml of first-morning urine will be collected from each subject and then immediately refrigerated. An enzyme-linked immunosorbent assay kit will be used to detect the protein level of AD7c-NTP in the urine specimens.

Imaging protocol

MRI data will be acquired using an integrated simultaneous 3.0 Tesla TOF PET/MR (SIGMA PET/MR, GE Healthcare, Milwaukee, WI, USA) at the Xuanwu Hospital of Capital Medical University. For each participant, simultaneous PET and 3.0 T MRI data will be obtained. Brain MR images will be inspected by an experienced neuroradiologist.

Positron emission tomography: All participants will be invited for optional [¹⁸F] florbetapir (AV-45) and [¹⁸F] fluordesoxyglucose (FDG) PET in 3-dimensional acquisition mode. The time duration between the FDG-PET and AV-45 PET is 3 days at least to eliminate the effect of the first tracer. For FDG-PET, each subject will be instructed to fast for at least 6 h and will have a confirmed serum glucose level below 8 mmol/L; 35 minutes dynamic scan is acquired about 40 minutes after an intravenous injection of 3.7 MBq/kg of ¹⁸F-FDG. For $A\beta$ -PET, 35 minutes dynamic scan is acquired about 40 minutes after an intravenous injection of 7-10mCi [¹⁸F] florbetapir. The PET data are acquired using a TOF-OSEM algorithm (time-of-flight ordered subset expectation maximization) with the following parameters: 8 iterations, 32 subsets matrix = 192×192, field of view (FOV)= 350×350, half-width height = 3.

1
2
3
4 Structural MRI: Parameters for T1-weighted 3D brain structural images are as following:
5 SPGR sequence, FOV=256×256 mm², matrix=256×256, slice thickness=1 mm, gap=0, slice
6 number=192, repetition time (TR) =6.9 ms, echo time (TE)=2.98 ms, inversion time (TI)=450
7 ms, flip angle =12°, voxel size = 1×1×1 mm³.
8
9
10

11 DTI: DTI data are obtained with Single-shot spin-echo diffusion-weighted EPI sequence
12 with following parameters: FOV=224×224mm², data matrix=112×112, slice thickness=2mm,
13 gap=0, slice number=70, slice order=interleaved, TR=16500 ms, TE=95.6 ms, 30 gradient
14 directions and 5 b0 images (b=1000s/mm²), voxel size =2×2×2 mm³.
15
16
17
18

19 Rs-fMRI: Single-shot gradient-echo EPI sequence is used for rs-fMRI with following
20 parameters: scan duration=8 minutes, FOV=224×224mm², data matrix=64×64, slice
21 thickness=4.0 mm, gap=1.0 mm, slice number=28, slice order=interleaved, TR=2000ms,
22 TE=30 ms, FA=90°, voxel size =3.5×3.5×4 mm³.
23
24
25
26

27 T-fMRI: T-fMRI: All participants will also be invited for a block design fMRI paradigm to
28 measure somatosensory mismatch negativity (MMN). We will use a self-designed air jet
29 pressure stimulation device, which could carry out 5.0 bar pressure somatosensory stimulation
30 in right index and middle finger respectively. The index and middle finger of the right hand
31 will be fixed by two adhesive tapes to restrict any movement during the experiment. The length
32 of the two air pipes from the air compressor to the apertures will be 6.0 meters, and the diameter
33 of the two stimulation apertures will be 1.0 millimeter. In addition, the distance between the
34 aperture and the center of the finger pad will be fixed at 5.0 millimeters for all subjects. Subjects
35 will be instructed to watch a video (without sound) presented on a custom designed screen and
36 to ignore stimulation to the fingers.
37
38
39
40
41
42
43
44
45

46 The functional MRI paradigm will have a total 9 min duration. In a block design, 8 control
47 blocks with 32s duration and 8 MMN blocks (also 32s duration). A constant stimulus onset
48 asynchrony of 500 ms will be employed for both the MMN and control conditions resulting in
49 40 stimuli per block. In devising the MMN and control blocks, we will take advantage of an
50 MMN paradigm in which two stimuli will be presented equiprobably and their presentation
51 order will be varied. In MMN blocks, stimulation will be arranged to compose alternating
52 'mini-sequences' of stimulus 1 (index finger, 5.0 bar, 300ms) and 2 (middle finger, 5.0 bar,
53 300ms). Mini-sequences will be 2, 3, or 4 repetitions of a single stimulus (each sequence length
54
55
56
57
58
59
60

1
2
3
4 is represented equiprobably) followed by a mini-sequence of the other stimuli, and so on. The
5
6 number of trials in a given mini-sequence will be various such that the occurrence of a switch
7
8 from stimulus 1 to stimulus 2 (and vice-versa) is irregular. As such, the switch trial stimuli will
9
10 be designated as deviants and will elicit the MMN. This basic stimulation paradigm, which has
11
12 proven to elicit robust MMNs, will be used for the MMN condition.^{47 48} For the matched control
13
14 condition to the aforementioned MMN condition, the same two stimuli will be alternated
15
16 sequentially to form a regular pattern (e.g. stimulus 1, stimulus 2, stimulus 1, stimulus 2, etc.).
17

18 19 **Imaging data analysis**

20
21 PET data analysis. The AV-45 and FDG PET scans will be preprocessed by the Statistical
22
23 Parametric Mapping version 12 (SPM 12; <https://www.fil.ion.ucl.ac.uk/spm/software/spm12>).
24
25 The structural images will be individually registered to the averaged PET images. The unified
26
27 segmentation method⁴⁹ will be then applied to all coregistered structural images. The PET
28
29 images will be spatially normalized to Montreal Neurological Institute (MNI) standard space
30
31 by using the forward parameters estimated during the unified segmentation and smoothed with
32
33 a Gaussian kernel of 8-mm full-width half-maximum (FWHM). Finally, voxel-wise AV-45 and
34
35 FDG PET standardized uptake value ratio (SUVR) will be normalized by the whole cerebellum
36
37 and pons as the reference regions, respectively. A global AV-45 PET SUVR value will be
38
39 estimated using a composite of the prefrontal, orbitofrontal, parietal, temporal, anterior
40
41 cingulate, and posterior cingulate and precuneus cortices.

42
43 SMRI data analysis. The cortical thickness analysis will be performed using the FreeSurfer
44
45 image analysis suite, version 5.3 (<http://surfer.nmr.mgh.harvard.edu>). We will construct models
46
47 of the boundaries between grey matter and white matter as well as pial surface.⁵⁰ Cortical
48
49 thickness measures will be obtained by calculating the distance between these surfaces.
50
51 Automated reconstruction and labeling will be performed using the default “recon-all”
52
53 command line. All generated images will be visually inspected for image and segmentation
54
55 quality and corrected manually if necessary. Subsequently, “lobesStrict” will be performed to
56
57 obtain a lobar annotation and consecutively imported for further statistical analyses. For the
58
59 voxel-based morphometry (VBM) analysis, structural images will be segmented into grey
60
matter (GM) tissue using the new segment function within SPM12. The diffeomorphic

1
2
3
4 anatomical registration using the exponentiated lie algebra (DARTEL) toolbox will be used to
5 generate a reference template object of the sample which will be warped into a standard MNI
6 space. The generated flow fields of each subject will be calculated and normalization
7 parameters will be then implemented to normalize the GM maps in the native space to the MNI
8 space. During the normalization process, the modulated images (local native amount of grey
9 matter) will be preserved. Images will be spatially smoothed with an 8 mm FWHM Gaussian
10 kernel. Finally, for each individual, we will obtain a smoothed GM volumetric map.
11 Additionally, the total intracranial volume (TIV) for each individual will be estimated by
12 summing the segmented GM, white matter, and cerebral spinal fluid (CSF). Then the smoothed
13 GM images of every individual will be used for subsequent statistical analysis.

14
15
16
17
18
19
20
21
22
23 DTI data analysis. Raw DTI data will be processed by using the Oxford Centre for Functional
24 MRI of the Brain (FMRIB) Software Library (FSL, <http://www.fmrib.ox.ac.uk/fsl>).⁵¹⁻⁵³ Initially,
25 the EddyCorrect tool will be used for correcting eddy current distortions and motion artifacts
26 by fine registration of the DTI images to a reference image (b0 image). The Brain Extraction
27 Tool (BET)⁵³ will be used for creating brain masks of all subjects and then a diffusion tensor
28 will be modeled at each voxel by using the least-squares algorithm fitting tensor model within
29 the DTI-FIT Tool.⁵⁴ Fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD),
30 and axial diffusivity (AxD) values of each voxel will be calculated based on the eigenvalues of
31 the tensor. Voxel-wise statistical analysis of the FA, MD, RD, and AxD data will be performed
32 using Tract-Based Spatial Statistics (TBSS).⁵⁵ All subjects' FA maps will be nonlinearly
33 coregistered to FMRIB58_FA template with FSL's nonlinear image registration algorithm.
34 Then, the mean FA image will be obtained and thinned to create a mean FA skeleton
35 representing the center of all tracts common to all subjects. Each subject's aligned FA data will
36 be then projected onto the FA skeleton to obtain their FA skeletons and deformation matrixes.
37 With the deformation matrixes, the skeletonized AxD, MD, and RD maps will be created for
38 every individual by the `tbss_non_FA` tool. These maps will be used for subsequent statistical
39 analysis.

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Rs-fMRI data analysis. Resting-state functional MR imaging will be preprocessed by using the
Data Processing Assistant for Resting-state fMRI (DPASF; <http://www.rfmri.org/DPARSF>).⁵⁶
The first 10 volumes will be discarded for image stabilization and participant's to adaptation to

1
2
3
4 the scanning. The remaining functional sequences will be first corrected for timing differences
5
6 between each slice and motion effects. Next, the structural image will be co-registered to the
7
8 mean functional image. Then the transformed structural images will be segmented to grey
9
10 matter, white matter, and CSF. The motion-corrected functional volumes will be spatially
11
12 normalized to MNI 152 standard space and resampled to 3 mm × 3 mm × 3 mm cubic voxels
13
14 by using the normalization parameters estimated during unified segmentation. The resulting
15
16 images will further undergo spatial smoothing (Gaussian kernel with an 8mm FWHM), linear
17
18 detrending and temporal filtering (0.01-0.08 Hz). Note, in order to avoid overestimating
19
20 regional homogeneity (ReHo) values, spatial smoothing will be conducted for individual ReHo
21
22 maps rather than during data preprocessing. Finally, nuisance signals (including Friston 24-
23
24 head motion parameters, the white matter, and CSF) will be extracted and regressed out from
25
26 the data to reduce the residual effects of nonneuronal factors. For the amplitude of low
27
28 frequency fluctuation (ALFF) analysis⁵⁷, the time series of each voxel will be transformed into
29
30 the frequency domain using a fast Fourier Transform. The square root of the power spectrum
31
32 will be calculated and averaged across 0.01-0.08 Hz. This averaged square root will be taken
33
34 as the ALFF value for this voxel. For the ReHo analysis⁵⁸, Kendall's coefficient of concordance
35
36 (KCC) will be computed on the ranked time series of a given voxel with its 26 nearest neighbors.
37
38 The resultant KCC will be taken as the ReHo values. The generated ALFF and ReHo images
39
40 will be used for statistical analysis.

41
42 Network analysis. We will construct structural cortical network based on grey matter
43
44 volumes.⁵⁹ The nodes will be defined as brain regions corresponding to automated anatomic
45
46 labeling (AAL) areas. The structural connections will be defined as statistical correlations
47
48 between pairs of average grey matter volumes in our study. A structural connection will be
49
50 considered to be existing if the correlation coefficient is statistically significant. Before the
51
52 correlation analysis, the effects of age, sex and total grey matter volume on grey matter volume
53
54 of regions will be adjusted. We will calculate Pearson correlation coefficients across individuals
55
56 between the average grey matter of every pair of regions and then an interregional correlation
57
58 matrix will be obtained for every individual. We will construct white matter network based on
59
60 fiber number. The network nodes will be defined as the 90 regions of interest corresponding to
AAL template. The weight of the network edge will be defined as the number of connected

1
2
3
4 fibers with two regions. The fiber number will be calculated through diffusion-tensor imaging
5 tractography as reported in our previous study.⁶⁰ To avoid spurious connections, a minimum
6 threshold of fiber number (weight of the edge=10) will be used. We will construct functional
7 network based on the average time sequence. The network nodes will be defined as the 90
8 regions of interest corresponding to AAL template. The network edge will be defined as the
9 partial correlation coefficients between the average time sequence of two regions and we will
10 obtain an incidence matrix. Non-significant correlations will be excluded. The network
11 analyses will be performed by the GRETNA toolbox (<http://www.nitrc.org/projects/gretna/>).⁶¹
12 The 'rich club coefficient' is defined as the density of connections between rich club nodes and
13 rich club regions in our study will be defined the top 13 brain regions with the highest degree
14 as reported in our previous study.⁶² A module is defined as a subset of nodes connected to the
15 other nodes in the same module than those outside the module.⁶³ We would like to use
16 Newman's metric to measure the modularity⁶⁴ and maximize the modularity parameter Q by
17 the algorithm proposed by Clauset et al.⁶⁵ The two parameters will be calculated for the
18 structural cortical network, white matter network and functional network constructed for each
19 individual. The values of the two measures will be calculated for every individual and be took
20 into the models construction.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 T-fMRI data analysis. We will use SPM12 to process and analyze the t-fMRI data. The first
37 10 volumes will be discarded due to unsteady magnetization. First, the functional images from
38 each run will be realigned. The structural image will be then coregistered to the first scan in the
39 functional image, and the resulting coregistered structural image will be normalized to MNI
40 152 standard space. Finally, these spatially normalized functional images will be smoothed
41 (Gaussian kernel with an 8mm FWHM).
42
43
44
45
46
47
48
49

50 **Statistical analysis**

51 **Baseline comparison between SCD convertors and SCD non-convertors**

52 All data (demographic information, clinical data, risk factors, neuropsychologic tests, blood
53 and urine biomarkers, multi-modal MRI biomarkers, glucose mentalism, and amyloid
54 deposition) will be described. The Shapiro-Wilk test and Q-Q plots will be used to confirm the
55 normality. All normally distributed continuous variables will be reported as the mean \pm SD.
56
57
58
59
60

1
2
3
4 Compared at baseline between SCD convertors and SCD non-convertors will be done with two-
5 sample t-test for continuous variables and chi-square test for categorical variables. Dunnett's
6 multiple comparison tests will be performed for comparison.
7

8
9 Statistical analyses of t-fMRI data will be subjected to a general linear model analysis. The
10 MMN condition will be served as the predictor of interest and will be modeled with a boxcar
11 function convolved with the canonical haemodynamic response function; the Control condition
12 will be served as a baseline. The beta estimates from the individual general linear models enter
13 a second level random effects analysis. Contrast maps will be created by applying paired t-tests
14 comparing the MMN versus control condition for each group separately as well as a two-sample
15 t-test for the between-groups comparison. Activation maps will be corrected ($P < 0.001$) by the
16 false discovery rate approach implemented in SPM.
17
18

19 **Longitudinal patterns in SCD-converters**

20
21 The longitudinal analysis in neuropsychological, plasma, urine and MRI variables in SCD-
22 convertors will be assessed. We will use the general linear mixed effects model to estimate the
23 individual's change in each variable.
24

25 **Statistical prediction models**

26
27 We will use the competing risk regression model to detect the association between possible risk
28 factors and endpoint. The endpoint event of our study is converting to MCI. Death before
29 conversion to MCI is considered as a competing risk in our study. Time to event is the date
30 difference between the baseline neuropsychological tests and the date at which the MCI or
31 dementia is first diagnosed.
32

33
34 Independent variables are listed in table 3 including features of baseline clinical
35 characteristics, blood, urine, MRI and PET biomarkers. considering the overfitting effect when
36 establishing the model, the least absolute shrinkage and selection operator (LASSO) model with
37 penalty parameter tuning will be used for variable screening. It is a data mining method for
38 shrinkage estimation and dimensionality reduction, overcoming processing difficulties caused by
39 high-dimensional data, and estimating the parameters more accurately. Then, we will perform the
40 sub-distribution hazard function model, which could evaluate hazards for the endpoint (MCI or
41 dementia) and competing (death) events, to establish the final multivariate models. Ten-fold
42 cross-validation is used to perform internal verification of the established models. The optimism-
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

corrected C-statistics will be used to evaluate the performance of risk prediction models.

To better clarify the relationship between possible risk factors and endpoint events, some confounding factors will be adjusted. Four models will be established in our study. Model 1 will simply take demographic data, lifestyle, clinical assessment, neuropsychological assessments, and SCD report into account. Model 2 will add ApoE genotype, plasma A β , and urine AD7c-NTP on the basis of model 1. Model 3 will take neuroimaging data into account on the basis of model 2 and model 4 will include amyloid-PET and FDG-PET on the basis of model 3.

The hazard ratio (HRs) with 95% confidence intervals are determined. A two-sided $p < 0.05$ is defined as statistical significance. All statistical tests were performed using R statistical software. The "glmnet" package will be used for the LASSO model analysis and the "cmprsk" package will be performed for the sub-distribution hazard function model.

Table 3 independent variable list

Types	
Demographic data	age; education level; family history of dementia; socioeconomic information
Lifestyle	nicotine and alcohol use; sleep quality (PSQI, RBDSQ, ESS); nutrition style
Clinical assessment	vascular risk factors (hypertension, hyperlipemia, diabetes, coronary heart disease, Fazekas score); medial temporal lobe atrophy scale; HAMA; HAMD; GDS
Neuropsychological assessment	AVLT-D; AVLT-R; STT-A; STT-B; BNT; AFT
SCD report	onset time; comparison with others; SCD-Q9; Ecog; consistency of SCD; inform report
Blood tests	ApoE genotype; Plasma β -amyloid
Urine tests	level of AD7c-NTP
MRI data	cortical thickness; grey matter volume; FA; MD; RD; AxD; ALFF; ReHo; network characteristic (rich-club coefficient, modality); MMN-related haemodynamic responses
PET data	global SUVR of FDG-PET and A β -PET

1
2
3 HAMA, the Hamilton Anxiety Scale; HAMD, the Hamilton Depression Scale; GDS, Geriatric
4 Depression Scale; AVLT, Auditory Verbal Learning Test; STT, Shape Trails Test; BNT,
5 Boston naming test; AFT, animal fluency test; SCD, subjective cognitive decline; FA,
6 fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; AxD, axial diffusivity;
7 ALFF, amplitude of low-frequency fluctuations; ReHo: regional homogeneity; SUVR,
8 standardized uptake volume ratios; MMN: mismatch negativity
9
10
11

12 **DISCUSSION**

13
14 The current study evaluates characteristics of SCD those presenting cognitive decline within
15 five years and furthermore, we will construct risk forecast models based on different
16 combinations of potential predictors achieve early diagnosis in the preclinical stage of AD.
17
18
19

20 Considering the long preclinical stage of AD and compensated cognitive function in the SCD
21 stage, the application of a refined SCD approach as an enrichment strategy for clinical trials
22 focusing on preclinical AD shows great promise. The SILCODE is a longitudinal study and we
23 will focus on features of SCD converters with multi-perspective analysis. Especially, we would
24 like to establish an integrated diagnostic system for early detection and prediction of SCD
25 progressing at the individual level. We aim to provide scientific evidence for a more effective
26 diagnosis of SCD due to AD and explore the underlying mechanism.
27
28
29
30
31
32
33

34 In this project, plasma A β , urine AD7c-NTP, and multi-modal MRI will also be included in
35 the predicting models. Plasma and urine biomarkers are non-invasive and feasible in clinical
36 practice. Previous studies have found their diagnostic efficiency in MCI and dementia,^{46 66} but
37 in SCD individuals, there are few pieces of evidence. So, this project also focuses on new
38 biomarkers and tries to identify their usage in the clinical scene. Additionally, through this
39 project, we would like to reveal the longitudinal patterns of involved clinical and MRI
40 biomarkers, especially the temporal sequences, which may provide basis for us to understand
41 the changes during disease progression.
42
43
44
45
46
47
48

49 The stage model theory proposes that human memory can be divided into three stages:
50 sensory memory, short-term memory, and long-term memory.⁶⁷ The MMN has been proposed
51 as an objective measure of the existence of auditory (visual, somatosensory) sensory memory
52 traces.⁶⁸ Previous studies have suggested that MMN may have the potential to measure the age-
53 related changes⁴⁷ or improve the diagnostic value for the early diagnosis of AD.⁶⁹ Although
54 much more SCD studies were concentrated on the short-term memory and long-term memory,¹⁸
55
56
57
58
59
60

1
2
3
4 70 71 there were quite few literatures about the sensory memory stage. SILCODE will investigate
5 the changes of the initial memory stage at the SCD population and the predictive value of
6 somatosensory MMN for disease progression in an exploratory way.
7
8

9 At last, cultural factors were found to impact on SCD by a cross-cultural comparison between
10 the US and China²¹, which indicates the need for SCD research in China. SILCODE is a
11 longitudinal study in China and the implement of SILCODE would provide characteristics of
12 SCD in China, which contribute to the harmonization of the SCD concept across cultural
13 borders.
14
15
16
17
18

21 **Author Contributions**

22
23 Xuanyu Li and Xiaoni Wang are joint first authors. Xuanyu Li and Xiaoni Wang are responsible
24 for the implementation of the trial, and manuscript draft and revision. Li Su is responsible for
25 the design and implement of imaging data analysis. Xiaochen Hu is responsible for the design
26 of SCD and clinical assessments. Ying Han is overall responsible for the study design,
27 implementation of the trial, manuscript draft and revision, and funding. All authors contributed
28 to the drafting of the manuscript and approved the final manuscript.
29
30
31
32
33
34
35

36 **Acknowledgments**

37
38 The authors would like to thank Kun Yang for helping them to revise the statistical section of
39 the manuscript. The authors would like to thank the participants of this study and patient
40 advisers for their support.
41
42
43
44
45

46 **Funding**

47
48 This work was supported by The National Key Research and Development Program of China
49 (2016YFC1306300), National Natural Science Foundation of China (Grant 61633018,
50 81801052, 81430037), Beijing Nature Science Foundation (7161009), Beijing Municipal
51 Commission of Health and Family Planning (PXM2019_026283_000002), Alzheimer's
52 Research UK (ARUK-SRF2017B-1), Addenbrooke's Charitable Trust, Alzheimer's Society
53 and The Lewy Body Society.
54
55
56
57
58
59
60

Competing interests

None declared.

Patient consent

All participation is based on written informed consent and the participants will be able to withdraw from the study at any time.

Ethics approval

Ethical approval of this has been obtained from the medical research ethics committee and institutional review board of the Xuanwu Hospital, Capital Medical University (ID: [2017]046).

Data sharing statement

Individual participant data that underlie future results published will not be publicly available but be available from our lab after deidentification. Proposals for access should be sent to hanying@xwh.ccmu.edu.cn. The date will be the beginning 9 months and ending 36 months following future article publication with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis.

REFERENCES

1. Scheltens P, Blennow K, Breteler MM, *et al*. Alzheimer's disease. *Lancet* 2016;388(10043):505-17.
2. Jack CR, Jr., Knopman DS, Jagust WJ, *et al*. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;9(1):119-28.
3. Honig LS, Vellas B, Woodward M, *et al*. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. *N Engl J Med* 2018;378(4):321-30.
4. Doody RS, Thomas RG, Farlow M, *et al*. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med* 2014;370(4):311-21.
5. Dubois B, Hampel H, Feldman HH, *et al*. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* 2016;12(3):292-323.
6. Jessen F, Amariglio RE, van Boxtel M, *et al*. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement* 2014;10(6):844-52.
7. Molinuevo JL, Rabin LA, Amariglio R, *et al*. Implementation of subjective cognitive decline criteria in research studies. *Alzheimers Dement* 2017;13(3):296-311.
8. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. *Annu Rev Clin Psychol* 2017;13:369-96.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
9. Mitchell AJ, Beaumont H, Ferguson D, *et al.* Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. *Acta Psychiatr Scand* 2014;130(6):439-51.
10. Dardenne S, Delrieu J, Sourdet S, *et al.* Memory Complaints and Cognitive Decline: Data from the GUIDAGE Study1. *J Alzheimers Dis* 2017;60(4):1567-78.
11. Jessen F, Wolfsgruber S, Wiese B, *et al.* AD dementia risk in late MCI, in early MCI, and in subjective memory impairment. *Alzheimers Dement* 2014;10(1):76-83.
12. Buckley RF, Maruff P, Ames D, *et al.* Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. *Alzheimers Dement* 2016;12(7):796-804.
13. Hessen E, Eckerstrom M, Nordlund A, *et al.* Subjective Cognitive Impairment Is a Predominantly Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study. *Dement Geriatr Cogn Dis Extra* 2017;7(1):1-14.
14. Vogel JW, Varga Dolezalova M, La Joie R, *et al.* Subjective cognitive decline and beta-amyloid burden predict cognitive change in healthy elderly. *Neurology* 2017;89(19):2002-09.
15. Bessi V, Mazzeo S, Padiglioni S, *et al.* From Subjective Cognitive Decline to Alzheimer's Disease: The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-Year Follow-Up Study. *J Alzheimers Dis* 2018;63(4):1523-35.
16. Fernandez-Blazquez MA, Avila-Villanueva M, Maestu F, *et al.* Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. *J Alzheimers Dis* 2016;52(1):271-81.
17. Wolfsgruber S, Kleineidam L, Wagner M, *et al.* Differential Risk of Incident Alzheimer's Disease Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. *J Alzheimers Dis* 2016;54(3):1135-46.
18. Jessen F, Spottke A, Boecker H, *et al.* Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther* 2018;10(1):15.
19. Slot RER, Verfaillie SCJ, Overbeek JM, *et al.* Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. *Alzheimers Res Ther* 2018;10(1):76.
20. Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, *et al.* FACEHBI: A Prospective Study of Risk Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study Rationale and Research Protocols. *J Prev Alzheimers Dis* 2017;4(2):100-08.
21. Wu Q. Subjective cognitive impairment of older adults: a comparison between the US and China. *Int J Methods Psychiatr Res* 2016;25(1):68-75.
22. Jackson JD, Rentz DM, Aghjayan SL, *et al.* Subjective cognitive concerns are associated with objective memory performance in Caucasian but not African-American persons. *Age Ageing* 2017;46(6):988-93.
23. Hao L, Wang X, Zhang L, *et al.* Prevalence, Risk Factors, and Complaints Screening Tool Exploration of Subjective Cognitive Decline in a Large Cohort of the Chinese Population. *J Alzheimers Dis* 2017;60(2):371-88.
24. Rabin LA, Smart CM, Crane PK, *et al.* Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. *J Alzheimers Dis* 2015;48 Suppl 1:S63-86.
25. Perquin M, Diederich N, Pastore J, *et al.* Prevalence of Dementia and Cognitive Complaints in the

- Context of High Cognitive Reserve: A Population-Based Study. *PLoS One* 2015;10(9):e0138818.
26. Gifford KA, Liu D, Romano R, 3rd, *et al.* Development of a subjective cognitive decline questionnaire using item response theory: a pilot study. *Alzheimers Dement (Amst)* 2015;1(4):429-39.
27. Tomaszewski Farias S, Mungas D, Harvey DJ, *et al.* The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales. *Alzheimers Dement* 2011;7(6):593-601.
28. Chen KL, Xu Y, Chu AQ, *et al.* Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment. *J Am Geriatr Soc* 2016;64(12):e285-e90.
29. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. *Control Clin Trials* 2000;21(6):552-60.
30. Licher S, Leening MJG, Yilmaz P, *et al.* Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies. *Am J Psychiatry* 2018:appiajp201818050566.
31. Pinto TCC, Machado L, Bulgacov TM, *et al.* Influence of Age and Education on the Performance of Elderly in the Brazilian Version of the Montreal Cognitive Assessment Battery. *Dement Geriatr Cogn Disord* 2018;45(5-6):290-99.
32. Bondi MW, Edmonds EC, Jak AJ, *et al.* Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis* 2014;42(1):275-89.
33. Zhao Q, Lv Y, Zhou Y, *et al.* Short-term delayed recall of auditory verbal learning test is equivalent to long-term delayed recall for identifying amnesic mild cognitive impairment. *PLoS One* 2012;7(12):e51157.
34. Guo Q, Hong Z, Shi W, *et al.* Boston naming test in Chinese elderly, patient with mild cognitive impairment and Alzheimer's dementia. *Chinese Mental Health Journal* 2006;20(2):81-84.
35. Guo Q, Jin L, Hong Z, *et al.* A Specific Phenomenon of Animal Fluency Test in Chinese Elderly. *Chinese Mental Health Journal* 2007;21(9):622-25.
36. Zhao Q, Guo Q, Li F, *et al.* The Shape Trail Test: application of a new variant of the Trail making test. *PLoS One* 2013;8(2):e57333.
37. McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7(3):263-9.
38. Bhome R, Huntley JD, Price G, *et al.* Clinical presentation and neuropsychological profiles of Functional Cognitive Disorder patients with and without co-morbid depression. *Cogn Neuropsychiatry* 2019:1-13.
39. Buckley R, Saling M, Ellis K, *et al.* Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. *Age Ageing* 2015;44(6):1012-9.
40. Buysse DJ, Reynolds CF, 3rd, Monk TH, *et al.* The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28(2):193-213.
41. Nomura T, Inoue Y, Kagimura T, *et al.* Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. *Sleep Med* 2011;12(7):711-3.
42. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14(6):540-5.
43. Guo QH, Zhou B, Zhao QH, *et al.* Memory and Executive Screening (MES): a brief cognitive test

- for detecting mild cognitive impairment. *BMC Neurol* 2012;12:119.
44. Llado-Saz S, Atienza M, Cantero JL. Increased levels of plasma amyloid-beta are related to cortical thinning and cognitive decline in cognitively normal elderly subjects. *Neurobiol Aging* 2015;36(10):2791-7.
45. Hanon O, Vidal JS, Lehmann S, *et al.* Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. *Alzheimers Dement* 2018;14(7):858-68.
46. Nakamura A, Kaneko N, Villemagne VL, *et al.* High performance plasma amyloid-beta biomarkers for Alzheimer's disease. *Nature* 2018;554(7691):249-54.
47. Strommer JM, Tarkka IM, Astikainen P. Somatosensory mismatch response in young and elderly adults. *Front Aging Neurosci* 2014;6:293.
48. Shinozaki N, Yabe H, Sutoh T, *et al.* Somatosensory automatic responses to deviant stimuli. *Brain Res Cogn Brain Res* 1998;7(2):165-71.
49. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage* 2005;26(3):839-51.
50. Fischl B, van der Kouwe A, Destrieux C, *et al.* Automatically parcellating the human cerebral cortex. *Cereb Cortex* 2004;14(1):11-22.
51. Smith SM, Jenkinson M, Woolrich MW, *et al.* Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage* 2004;23 Suppl 1:S208-19.
52. Woolrich MW, Jbabdi S, Patenaude B, *et al.* Bayesian analysis of neuroimaging data in FSL. *Neuroimage* 2009;45(1 Suppl):S173-86.
53. Smith SM. Fast robust automated brain extraction. *Hum Brain Mapp* 2002;17(3):143-55.
54. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophys J* 1994;66(1):259-67.
55. Smith SM, Jenkinson M, Johansen-Berg H, *et al.* Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. *Neuroimage* 2006;31(4):1487-505.
56. Chao-Gan Y, Yu-Feng Z. DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI. *Front Syst Neurosci* 2010;4:13.
57. Zang YF, He Y, Zhu CZ, *et al.* Altered baseline brain activity in children with ADHD revealed by resting-state functional MRI. *Brain Dev* 2007;29(2):83-91.
58. Zang Y, Jiang T, Lu Y, *et al.* Regional homogeneity approach to fMRI data analysis. *Neuroimage* 2004;22(1):394-400.
59. Yao Z, Zhang Y, Lin L, *et al.* Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. *PLoS Comput Biol* 2010;6(11):e1001006.
60. Shu N, Wang X, Bi Q, *et al.* Disrupted Topologic Efficiency of White Matter Structural Connectome in Individuals with Subjective Cognitive Decline. *Radiology* 2018;286(1):229-38.
61. Wang J, Wang X, Xia M, *et al.* GREYNA: a graph theoretical network analysis toolbox for imaging connectomics. *Front Hum Neurosci* 2015;9:386.
62. Yan T, Wang W, Yang L, *et al.* Rich club disturbances of the human connectome from subjective cognitive decline to Alzheimer's disease. *Theranostics* 2018;8(12):3237-55.
63. Radicchi F, Castellano C, Cecconi F, *et al.* Defining and identifying communities in networks. *Proc Natl Acad Sci U S A* 2004;101(9):2658-63.
64. Newman ME. Fast algorithm for detecting community structure in networks. *Phys Rev E Stat Nonlin Soft Matter Phys* 2004;69(6 Pt 2):066133.
65. Clauset A, Newman ME, Moore C. Finding community structure in very large networks. *Phys Rev*

E

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stat Nonlin Soft Matter Phys 2004;70(6 Pt 2):066111.

66. Zhang J, Zhang CH, Li RJ, *et al.* Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis* 2014;40(1):153-9.

67. McGaugh JL. Time-dependent processes in memory storage. *Science* 1966;153(3742):1351-8.

68. Naatanen R. Mismatch negativity: clinical research and possible applications. *Int J Psychophysiol* 2003;48(2):179-88.

69. Papaliagkas VT, Anogianakis G, Tsolaki MN, *et al.* Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels. *Dement Geriatr Cogn Disord* 2009;28(1):30-5.

70. Erk S, Spottke A, Meisen A, *et al.* Evidence of neuronal compensation during episodic memory in subjective memory impairment. *Arch Gen Psychiatry* 2011;68(8):845-52.

71. Rodda JE, Dannhauser TM, Cutinha DJ, *et al.* Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. *Int J Geriatr Psychiatry* 2009;24(8):865-74.

Figure legend

Figure 1 Flow chart of SILCODE. SCD, subjective cognitive decline; fMRI, functional MRI; FDG-PET, fludesoxyglucose positron emission tomography; A β -PET, β -amyloid positron emission tomography; MoCA: Montreal Cognitive Assessment-basic




Figure 1 Flow chart of SILCODE. SCD, subjective cognitive decline; fMRI, functional MRI; FDG-PET, fluorodesoxyglucose positron emission tomography; Aβ-PET, β-amyloid positron emission tomography; MoCA: Montreal Cognitive Assessment-basic

90x90mm (300 x 300 DPI)

BMJ Open

**Sino Longitudinal Study on Cognitive Decline (SILCODE):
protocol for a Chinese longitudinal observational study to
develop risk prediction models of conversion to mild
cognitive impairment in individuals with subjective
cognitive decline**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028188.R2
Article Type:	Protocol
Date Submitted by the Author:	15-May-2019
Complete List of Authors:	Li, Xuanyu; XuanWu Hospital of Capital Medical University, Neurology wang, Xiaoni; XuanWu Hospital of Capital Medical University, , Neurology Su, Li; University of Cambridge, Psychiatry; Southwest University, Faculty of Psychology, Sino-Britain Centre for Cognition and Ageing Research Hu, Xiaochen; University of Cologne, Medical Faculty, Department of Psychiatry and Psychotherapy Han, Ying; XuanWu Hospital of Capital Medical University, Neurology; Beijing Institute for Brain Disorders, Center of Alzheimer's Disease
Primary Subject Heading:	Neurology
Secondary Subject Heading:	Neurology
Keywords:	Dementia < NEUROLOGY, Magnetic resonance imaging < RADIOLOGY & IMAGING, Nuclear radiology < RADIOLOGY & IMAGING

SCHOLARONE™
Manuscripts

Title Page:**Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline**

Xuanyu Li^{1#}, Xiaoni Wang^{1#}, Li Su^{2,3}, Xiaochen Hu⁴, Ying Han^{1,5,6,7*}

1. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China, 100053
2. Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, CB2 1TN
3. Sino-Britain Centre for Cognition and Ageing Research, Faculty of Psychology, Southwest University, Chongqing, China, 400715
4. Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany, 50937
5. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China, 100053
6. Beijing Institute of Geriatrics, Beijing, China, 100053
7. National Clinical Research Center for Geriatric Disorders, Beijing, China, 100053

[#]These authors contributed equally to this work

*Corresponding Author: Ying Han, E-mail: hanying@xwh.ccmu.edu.cn, Tel: 13621011941

Keywords: Alzheimer's disease; subjective cognitive decline; magnetic resonance imaging; positron emission tomography; conversion

Word count: 5495

ABSTRACT

Introduction Understanding the biological mechanism of subjective cognitive decline (SCD) in preclinical Alzheimer's disease (AD) and identifying those who will soon convert to mild cognitive impairment (MCI) are critical for developing appropriate strategies for early diagnosis and intervention of AD. We present the study protocol of the Sino Longitudinal Study on Cognitive Decline (SILCODE), a longitudinal observational study focusing on SCD in the context of AD.

Methods and analysis Within SILCODE, approximately 800 subjects with SCD who are between 50 and 79 years old will be recruited through standardized public advertisements or memory clinics. They will undergo extensive assessment, including clinical and neuropsychological assessments, blood sample collection for plasma beta-amyloid and ApoE genotype, urine samples collection for AD7c-NTP, and multimodal MRI scans (structural MRI, diffusion tensor imaging, resting-state functional MRI and optional task-based functional MRI) as well as optional glucose metabolism and amyloid positron emission tomography. Subjects will be contacted by telephone every 3 months and interviewed, on average, every 15 months for five years. The study endpoint is the development of mild cognitive impairment or dementia. Jak & Bondi's actuarial neuropsychological method will be used for diagnosis of MCI. The least absolute shrinkage and selection operator (LASSO) logistic regression model followed by the sub-distribution hazard function model with death as a competing risk will be constructed to establish risk prediction models.

Ethics and dissemination The ethics committee of the Xuanwu Hospital of Capital Medical University has approved this study protocol (ID: [2017]046). The results will be published in peer-reviewed journals and presented at national and international scientific conferences.

Trial registration NCT03370744; pre-results.

Article summary

Strengths and limitations of this study

- A strength of this study is the use of multiple markers (clinical, blood, urine and imaging markers) to establish models predicting conversion from SCD to MCI, which will provide references for clinical applications of SCD.

- This longitudinal study could enrich the understanding of SCD by examining a large-scale Chinese population because cultural factors have an impact on SCD.
- The relatively short follow-up duration (5 years) of this study allows longitudinal data to be analyzed only in an exploratory way.
- The study results will be limited by the research environment in that individuals will be recruited from memory clinics and volunteer samples, without community-based or population-based samples.

INTRODUCTION

Alzheimer's disease (AD) is the most common neurodegenerative disease and one of the greatest healthcare challenges of the 21st century.¹ It has been revealed that pathophysiology starts many years before the onset of clinical symptoms.² Several recent clinical trials of A β -lowering therapies in the mild or moderate dementia stage and even mild cognitive impairment stage have failed,^{3 4} further encouraging researchers to shift their focus to the preclinical stage of AD as a target for new treatments.⁵

Subjective cognitive decline (SCD) refers to self-perceived cognitive decline relative to a previously normal status, without impaired performance on standardized neuropsychological tests.^{6 7} Evidence from recent studies suggests that SCD may be one of the earliest symptomatic manifestations of AD.^{6 8} Previous studies have found that individuals with SCD have a higher conversion rate and shorter conversion time to mild cognitive impairment (MCI) and dementia than normal controls (NC).⁹⁻¹² SCD may be an early trigger for help-seeking¹³, and we have observed that the number of individuals with SCD presenting to the healthcare system (e.g., memory clinics) is increasing in our clinical practice as awareness of AD dementia increases in China. Individuals with SCD are ideal for ultra-early diagnosis and intervention trials.

However, the heterogeneous nature of SCD limits its value in clinical applications. Research to date has focused on factors for predicting the risk of MCI/AD progression in SCD.¹⁴⁻¹⁷ Though some longitudinal and observational studies of SCD are ongoing,¹⁸⁻²⁰ there are few data available from China or anywhere else in Asia. However, SCD is subject to influence by various cultural factors including factors relate to language, social stigmatization of cognitive problems, styles of responding on self-reported measures (e.g., extremity of answers), tolerance of slowly

1
2
3
4 progressive cognitive decline in ageing and others.²¹ The association between objective
5 cognitive performance and SCD is different across races.²² Our group reported that the
6 prevalence of SCD was 14.4% in the Shunyi District of Beijing, China,²³ which is different
7 from the prevalence of SCD reported in Western countries.^{24 25} Thus, there is a need for
8 additional findings from longitudinal studies based on large-scale Chinese populations.
9
10
11
12

13 The Alliance for Preclinical AD in China, belonging to the National Clinical Research Center
14 for Geriatric Disorders, is a national multicenter research platform that is dedicated to the
15 development of clinical, neuroimaging, genetic, and biochemical biomarkers for the early
16 detection and tracking of AD. Its sites include more than 180 member hospitals/research
17 institutes across China. The alliance is led by Professor Han and focuses on the early detection
18 of SCD during preclinical AD; it also develops and provides standard operating procedures and
19 quality control for harmonized data and material acquisition and storage across all sites.
20
21
22
23
24
25
26

27 In this protocol, we introduce in detail the design of the Sino Longitudinal Study on
28 Cognitive Decline (SILCODE) study. This is an ongoing longitudinal observational study based
29 on the multicenter research platform of the Alliance for Preclinical AD in China and focusing
30 on SCD in the context of AD. The main aim of SILCODE is to estimate cognitive decline and
31 establish statistical prediction models for the outcomes of SCD in elderly Chinese people.
32
33
34
35
36
37

38 **METHODS**

39 **Overall study design**

40 This observational longitudinal study will take place in China and will recruit people with SCD.
41 During the baseline period, all eligible subjects with SCD will be invited to receive clinical and
42 neuropsychological examinations, blood tests, urine tests and multimodal MRI [including
43 structural MRI (sMRI), diffusion tensor imaging (DTI) and resting-state functional MRI (rs-
44 fMRI)] sequentially as shown in figure 1. Glucose metabolism and amyloid positron emission
45 tomography (PET) and task-based fMRI (t-fMRI) will be performed as well if the subject agrees
46 to them. A semi-structured interview¹⁸ as well as the SCD questionnaire²⁶ and the Measurement
47 of Everyday Cognition (ECog)²⁷ will be used to assess SCD. The maximum interval between
48 neuropsychological tests and other data collection will be within three months. Subjects will be
49 contacted by telephone every 3-months and will be interviewed, on average, every 15 months
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 for five years (4 time points). The Montreal Cognitive Assessment-Basic (MoCA-B)²⁸ subtests
5 (language, delayed recall and orientation) will be administered during the call. Participants
6 expressing significant cognitive decline on the telephone will be interviewed ahead of time for
7 the next follow-up. During the follow-up visits with interviews, evaluations including clinical
8 and neuropsychological examinations, blood tests, urine tests, and multimodal MRI as well as
9 optional glucose metabolism PET and t-fMRI will be conducted, on average, every 15 months.
10 At each follow-up visit, diagnoses will be re-evaluated under the supervision of two
11 neurologists. Figure 1 provides the overall study outline.
12
13
14
15
16
17
18
19
20

21 **Patient and public involvement**

22
23 Patients and the public will not be involved in the development of the research question or the
24 design of the study. Patients will not be involved in the recruitment of participants or the
25 conduct of the study. The general results will be disseminated to participants through public
26 education activities.
27
28
29
30
31
32

33 **Sample size calculation**

34
35 The formula proposed by Hsieh and Lavori²⁹ was used to estimate the sample size in our study with
36 the software PASS (version 15.0.5). According to a previous meta-analysis,⁹ the cumulative
37 conversion proportion was 24.4% over a mean follow-up period of 4.1 years. We assumed that
38 the power ($1-\beta$) was 80%, α was 0.05 and the rate of loss to follow-up was 20%. Due to the
39 lack of statistical data on SCD, we calculated the sample size with data reported by Licher et
40 al³⁰ and Pinto et al³¹ (hazard ratio= 1.03, standard deviation=8.2, $R^2=0.127$) from cognitively
41 normal elderly subjects for the association between age and cognitive decline. This calculation
42 rendered a total sample size of 762. Considering the need for internal validation, we will recruit
43 at least 800 subjects.
44
45
46
47
48
49
50
51
52
53

54 **Recruitment of participants**

55
56 Participants will be consecutively recruited through standardized public advertisements and
57 through referrals from general physicians, memory clinics, or informants. Residents who meet
58 the inclusion criteria will be recruited. Written informed consent will be acquired from each
59
60

subject before enrolment.

Diagnostic criteria for SCD, MCI and dementia

SCD is defined by the research criteria for pre-MCI (SCD) proposed by Jessen et al in 2014⁶:

(1) Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; (2) Normal age-, gender-, and education-adjusted performance on standardized cognitive tests.

MCI is defined by an actuarial neuropsychological method proposed by Jak and Bondi.³² Participants are considered to have MCI if they meet any one of the following three criteria and fail to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative means) on both measures in at least one cognitive domain (memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled (memory, language, or speed/executive function); (3) the Functional Activities Questionnaire (FAQ) ≥ 9 . The normative means in our study are from Guo and his team in a Chinese population.³³⁻³⁶ Measures and normative means are shown in table 1.

The diagnosis of AD dementia is based on the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, and the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging–Alzheimer’s Association workgroups (NIA-AA),³⁷ and a total CDR score ≥ 1 .

Table 1 Cognitive domains, neuropsychological tests and normative means

Cognitive domains	Neuropsychological tests	Normative means
Memory	Auditory Verbal Learning Test- long delayed memory ³³	50-59 years old: 5; 60-69 years old: 4; 70-79 years old: 3
	Auditory Verbal Learning Test- recognition ³³	50-59 years old: 20; 60-69 years old: 19; 70-79 years old: 18
Language	Animal Fluency Test ³⁵	junior middle school: 12; high school: 13; college: 14
	30-item Boston Naming Test ³⁴	junior middle school: 20; high school: 21;

		college: 22
speed/executive	Shape Trail Test Part A ³⁶	50-59 years old: 70s; 60-69 years old: 80s; 70-79 years old: 100s
	Shape Trail Test Part B ³⁶	50-59 years old: 180s; 60-69 years old: 200s; 70-79 years old: 240s

Inclusion/exclusion criteria

The inclusion criteria are as follows: (1) 50-79 years old, right-handed and Mandarin-speaking subjects; (2) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; (3) concerns (worries) associated with memory complaint; and (4) failure to meet the criteria for MCI or dementia.

The exclusion criteria are as follows: (1) History of stroke. (2) Current major psychiatric diagnoses such as severe depression and anxiety. When mild or moderate symptoms of psychiatric disorders are suspected, patients will not be excluded³⁸. They will be evaluated by a psychiatrist to determine whether the psychiatric diagnoses are the cause of SCD. (3) Other neurological conditions that could cause cognitive decline (e.g., brain tumours, Parkinson's disease, encephalitis, or epilepsy) rather than AD spectrum disorders. (4) Other diseases that could cause cognitive decline (e.g., thyroid dysfunction, severe anaemia, syphilis, or HIV); (5) history of psychosis or congenital mental developmental delay. (6) Cognitive decline caused by traumatic brain injury. (7) Inability to complete the study protocol or presence of contraindications for MRI.

Clinical progression

At each follow-up visit, diagnoses will be re-evaluated under the supervision of two neurologists. The main outcome measure of clinical progression in our study is conversion to MCI or AD dementia. The time to event is the interval between the baseline neuropsychological tests and the date at which the MCI is first diagnosed. For those who bypass the diagnosis of MCI during follow-up, the time between the baseline neuropsychological tests and first diagnosis of dementia is defined as the time to event in our study.

Assessments of subjective cognitive functioning

A semi-structured interview used by the DELCODE study will be employed in this project to evaluate the details of SCD.¹⁸ It includes information about the onset time, concerns, comparison with others, and the history of visiting a physician not only for the memory domain but also for language, attention, and executive control. We will also require informant reports in the evaluation of the self-reported information as suggested by the Subjective Cognitive Decline Initiative Working Group.^{7 39}

For quantitative assessment of the severity of SCD, we will use a newly developed SCD questionnaire including nine reliable SCD items (table 2), which are characterized by different domains, such as global memory functioning and daily activities ability.^{23 26} In addition, the 12-item ECog²⁷ will also be applied to all participants to measure SCD severity. These questionnaires will not be inclusion criteria and will be considered only for statistical analysis.

Table 2 items included in SCD questionnaire²⁶

Items
Do you think you have problems with your memory?
Do you have difficulty remembering a conversation from a few days ago?
Do you have complaints about your memory in the last 2 years?
How often is the following a problem for you: Personal dates
How often is the following a problem for you: Phone numbers you use frequently
On a whole, do you think that you have problems remembering things that you want to do or say?
How often is the following a problem for you: Going to the store and forgetting what you wanted to buy
Do you think that your memory is worse than 5 years ago?
Do you feel you are forgetting where things were placed?

Clinical, risk factor and neuropsychological assessments

The clinical assessments include a structured medical history, physical examination, routine laboratory tests (including blood tests, biochemical tests, thyroid function tests, vitamin B12 status, folic acid status, *Treponema pallidum*-specific antibodies and HIV antibodies) and MRI (T1 and FLAIR) for medial temporal atrophy scale and Fazekas score.

1
2
3
4 For risk factors of AD, all subjects and their informants will provide the following
5 information: family history, vascular risk factors, occupation/retirement, socioeconomic status,
6 cigarettes, and alcohol use, and nutrition style. Additionally, the Pittsburgh sleep quality index
7 (PSQI)⁴⁰, Rapid Eye Movement (REM) Sleep Behaviour Disorder Screening Questionnaire
8 (RBDSQ)⁴¹ and the Epworth Sleepiness Scale (ESS)⁴² will be used for sleep quality assessment
9

10
11
12
13 The neuropsychological tests are selected for comparability with other similar ongoing
14 studies (e.g., DELCODE).¹⁸ To avoid deviations in the evaluation, the neuropsychologists
15 performing the cognitive tests will be trained according to standard guidelines. The kappa
16 coefficient (Fleiss' kappa) will be used to measure the assessment agreement among the
17 neuropsychologists. Neuropsychological results will be double-checked. The
18 neuropsychological battery (table 1) measures different cognitive domains including episodic
19 memory (Auditory Verbal Learning Test-HuaShan version [AVLT-H]),³³ language (Animal
20 Fluency Test,³⁵ 30-item Boston Naming Test³⁴ and speed/executive function (Shape Trail Test
21 Parts A and B³⁶). In addition, the SILCODE study will implement tests for global cognition,
22 daily life ability and neuropsychiatric assessment, including MoCA-B,²⁸ the memory and
23 executive screening (MES),⁴³ the CDR, FAQ, the 15-item short form of the Geriatric
24 Depression Scale (GDS), the Hamilton Anxiety Scale (HAMA), the Hamilton Depression Scale
25 (HAMD) and the Neuropsychiatric Inventory (NPI).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Blood tests**

42 **ApoE genotype**

43
44 SNPs rs7412 and rs429358 form the ApoE $\epsilon 2/\epsilon 3/\epsilon 4$ haplotype. ApoE will be genotyped using
45 the standard Sanger sequencing method (Sangon, Shanghai, China) using the following primers:
46 5'-ACGCGGGCACGGCTGTCCAAGG-3' (forward) and 5'-
47 GGCGCTCGCGGATGGCGCTGA-3' (reverse). ApoE will be amplified using the following
48 conditions: 1 cycle of 98 °C for 10 s, 35 cycles of 72 °C for 5 s, 1 cycle of 72 °C for 5 minutes.
49 PCR was performed in a final volume of 30 μ l, containing 10 pmol of forward and reverse
50 primers and 50 ng of genomic DNA template, using PrimeSTAR HS DNA Polymerase with
51 GC Buffer (Takara Bio).
52
53
54
55
56
57
58
59

60 **Plasma β -amyloid**

1
2
3
4 Recently, some studies found that plasma amyloid level was correlated with cognitive capacity
5 and cerebrospinal fluid amyloid protein.^{44 45} In particular, when predicting brain amyloid
6 deposition, the accuracy of the composite biomarker (amyloid- β precursor protein 669-
7 711/A β 1-42 and A β 1-40/A β 1-42 ratios) could be approximately equal to 90%.⁴⁶ Therefore, we
8 would like to identify whether the plasma β -amyloid is also associated with cognitive decline
9 in SCD individuals. Plasma A β will be determined using a commercially available kit, V-PLEX
10 A β Peptide Panel 1 (6E10) Kit (K15200E) (MesoScale Diagnostics LLC, Rockville,
11 USA). A β peptide levels from each blood draw will be measured in duplicate using the same
12 aliquot.
13
14
15
16
17
18
19
20
21
22

23 **Urine tests**

24
25 Ten millilitres of first morning voided urine will be collected from each subject and then
26 immediately refrigerated. An enzyme-linked immunosorbent assay kit will be used to detect
27 the protein level of AD7c-NTP in the urine specimens.
28
29
30
31
32

33 **Imaging protocol**

34
35 MRI data will be acquired using an integrated simultaneous 3.0 Tesla TOF PET/MR (SIGNA
36 PET/MR, GE Healthcare, Milwaukee, WI, USA) at the Xuanwu Hospital of Capital Medical
37 University. For each participant, simultaneous PET and 3.0 T MRI data will be obtained. Brain
38 MR images will be inspected by an experienced neuroradiologist.
39
40
41

42 Positron emission tomography: All participants will be invited for optional [¹⁸F] florbetapir
43 (AV-45) and [¹⁸F] fluorodeoxyglucose (FDG) PET in 3-dimensional acquisition mode. The
44 time duration between the FDG-PET and AV-45 PET is at least 3 days to eliminate the effect
45 of the first tracer. For FDG-PET, each subject will be instructed to fast for at least 6 h and must
46 have a confirmed serum glucose level below 8 mmol/L; 35 minutes dynamic scan is acquired
47 approximately 40 minutes after an intravenous injection of 3.7 MBq/kg of 18F-FDG. For A β -
48 PET, a 35-minute dynamic scan is acquired approximately 40 minutes after an intravenous
49 injection of 7-10 mCi [¹⁸F] florbetapir. The PET data are acquired using a TOF-OSEM
50 algorithm (time-of-flight ordered subset expectation maximization) with the following
51 parameters: 8 iterations, 32 subsets matrix = 192 \times 192, field of view (FOV)= 350 \times 350, half-
52
53
54
55
56
57
58
59
60

width height = 3.

Structural MRI: Parameters for T1-weighted 3D brain structural images are as follows: SPGR sequence, FOV=256×256 mm², matrix=256×256, slice thickness=1 mm, gap=0, slice number=192, repetition time (TR) =6.9 ms, echo time (TE)=2.98 ms, inversion time (TI)=450 ms, flip angle =12°, voxel size = 1×1×1 mm³.

DTI: DTI data are obtained with a single-shot spin-echo diffusion-weighted EPI sequence with the following parameters: FOV=224×224mm², data matrix=112×112, slice thickness=2 mm, gap=0, slice number=70, slice order=interleaved, TR=16500 ms, TE=95.6 ms, 30 gradient directions and 5 b0 images (b=1000 s/mm²), voxel size =2×2×2 mm³.

Rs-fMRI: A single-shot gradient-echo EPI sequence is used for rs-fMRI with the following parameters: scan duration=8 minutes, FOV=224×224mm², data matrix=64×64, slice thickness=4.0 mm, gap=1.0 mm, slice number=28, slice order=interleaved, TR=2000 ms, TE=30 ms, FA=90°, voxel size =3.5×3.5×4 mm³.

T-fMRI: All participants will also be invited for a block design fMRI paradigm to measure somatosensory mismatch negativity (MMN). We will use a custom-designed air jet pressure stimulation device, which can apply 5.0-bar pressure somatosensory stimulation to the right index or middle finger. The index and middle finger of the right hand will be fixed in place with two pieces of adhesive tapes to restrict any movement during the experiment. The length of the two air pipes from the air compressor to the apertures will be 6.0 metres, and the diameter of the two stimulation apertures will be 1.0 millimetres. In addition, the distance between the aperture and the centre of the finger pad will be fixed at 5.0 millimetres for all subjects. Subjects will be instructed to watch a video (without sound) presented on a custom designed screen and to ignore stimulation to the fingers.

The functional MRI paradigm will have a total duration of 9 minutes. In a block design, 8 control blocks with 32 s duration and 8 MMN blocks (also 32 s duration) will be used. A constant stimulus onset asynchrony of 500 ms will be employed for both the MMN and control conditions resulting in 40 stimuli per block. In devising the MMN and control blocks, we will take advantage of an MMN paradigm in which two stimuli will be presented equiprobably and their presentation order will be varied. In MMN blocks, stimulation will be arranged to compose alternating 'mini-sequences' of stimulus 1 (index finger, 5.0 bar, 300 ms) and 2 (middle finger,

1
2
3
4 5.0 bar, 300 ms). Mini-sequences will be 2, 3, or 4 repetitions of a single stimulus (each
5 sequence length is represented equiprobably), followed by a mini-sequence of the other stimuli,
6 and so on. The number of trials in a given mini-sequence will vary such that the occurrence of
7 a switch from stimulus 1 to stimulus 2 (and vice-versa) is irregular. As such, the switch trial
8 stimuli will be designated as deviants and will elicit the MMN. This basic stimulation paradigm,
9 which has proven to elicit robust MMNs, will be used for the MMN condition.^{47 48} For the
10 matched control condition to the aforementioned MMN condition, the same two stimuli will be
11 alternated sequentially to form a regular pattern (e.g., stimulus 1, stimulus 2, stimulus 1,
12 stimulus 2, etc.).

23 **Imaging data analysis**

24 PET data analysis. The AV-45 and FDG-PET scans will be preprocessed by Statistical
25 Parametric Mapping version 12 (SPM 12; <https://www.fil.ion.ucl.ac.uk/spm/software/spm12>).
26 The structural images will be individually registered to the averaged PET images. The unified
27 segmentation method⁴⁹ will then be applied to all coregistered structural images. The PET
28 images will be spatially normalized to Montreal Neurological Institute (MNI) standard space
29 by using the forward parameters estimated during the unified segmentation and smoothed with
30 an 8-mm full width at half maximum (FWHM) Gaussian kernel. Finally, the voxel-wise AV-
31 45 and FDG-PET standardized uptake value ratio (SUVR) will be normalized by the whole
32 cerebellum and pons as the reference regions, respectively. A global AV-45 PET SUVR value
33 will be estimated using a composite of the prefrontal, orbitofrontal, parietal, temporal, anterior
34 cingulate, and posterior cingulate and precuneus cortices.

35 SMRI data analysis. The cortical thickness analysis will be performed using the FreeSurfer
36 image analysis suite, version 5.3 (<http://surfer.nmr.mgh.harvard.edu>). We will construct models
37 of the boundaries between the grey matter and the white matter as well as the pial surface.⁵⁰
38 Cortical thickness measures will be obtained by calculating the distance between these surfaces.
39 Automated reconstruction and labelling will be performed using the default “recon-all”
40 command line. All generated images will be visually inspected for image and segmentation
41 quality and corrected manually if necessary. Subsequently, “lobesStrict” will be performed to
42 obtain a lobar annotation and consecutively imported for further statistical analyses. For the
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 voxel-based morphometry (VBM) analysis, structural images will be segmented into grey
5 matter (GM) tissue using the new segment function within SPM12. The diffeomorphic
6 anatomical registration through the exponentiated Lie algebra (DARTEL) toolbox will be used
7 to generate a reference template object of the sample that will be warped into a standard MNI
8 space. The generated flow fields of each subject will be calculated and normalization
9 parameters will be then implemented to normalize the GM maps in the native space to the MNI
10 space. During the normalization process, the modulated images (local native amount of grey
11 matter) will be preserved. Images will be spatially smoothed with an 8 mm FWHM Gaussian
12 kernel. Finally, for each individual, we will obtain a smoothed GM volumetric map.
13 Additionally, the total intracranial volume (TIV) for each individual will be estimated by
14 summing the segmented GM, white matter, and cerebral spinal fluid (CSF). Then, the smoothed
15 GM images of every individual will be used for subsequent statistical analysis.

16
17 DTI data analysis. Raw DTI data will be processed using the Oxford Centre for Functional MRI
18 of the Brain (FMRIB) Software Library (FSL, <http://www.fmrib.ox.ac.uk/fsl>).⁵¹⁻⁵³ Initially, the
19 EddyCorrect tool will be used to correct eddy current distortions and motion artefacts by fine
20 registration of the DTI images to a reference image (b0 image). The Brain Extraction Tool
21 (BET)⁵³ will be used for creating brain masks of all subjects, and then a diffusion tensor will
22 be modelled at each voxel by using the least- squares algorithm fitting tensor model within the
23 DTI-FIT Tool.⁵⁴ Fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD),
24 and axial diffusivity (AxD) values of each voxel will be calculated based on the eigenvalues of
25 the tensor. Voxel-wise statistical analysis of the FA, MD, RD, and AxD data will be performed
26 using tract-based spatial statistics (TBSS).⁵⁵ All subjects' FA maps will be nonlinearly
27 coregistered to the FMRIB58_FA template with FSL's nonlinear image registration algorithm.
28 Then, the mean FA image will be obtained and thinned to create a mean FA skeleton
29 representing the centre of all tracts common to all subjects. Each subject's aligned FA data will
30 then be projected onto the FA skeleton to obtain their FA skeletons and deformation matrixes.
31 With the deformation matrixes, the skeletonized AxD, MD, and RD maps will be created for
32 every individual by the `tbss_non_FA` tool. These maps will be used for subsequent statistical
33 analysis.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Rs-fMRI data analysis. Resting-state functional MR imaging will be preprocessed using the

1
2
3
4 Data Processing Assistant for Resting-state fMRI (DPASF; <http://www.rfmri.org/DPARSEF>).⁵⁶

5
6 The first 10 volumes will be discarded for image stabilization and the participant's to adaptation
7
8 to the scanning. The remaining functional sequences will be first corrected for timing
9
10 differences between each slice and motion effects. Next, the structural image will be
11
12 coregistered to the mean functional image. Then, the transformed structural images will be
13
14 segmented into grey matter, white matter, and CSF. The motion-corrected functional volumes
15
16 will be spatially normalized to MNI 152 standard space and resampled to 3 mm × 3 mm × 3
17
18 mm cubic voxels by using the normalization parameters estimated during unified segmentation.
19
20 The resulting images will further undergo spatial smoothing (Gaussian kernel with 8 mm
21
22 FWHM), linear detrending and temporal filtering (0.01-0.08 Hz). To avoid overestimating
23
24 regional homogeneity (ReHo) values, spatial smoothing will be conducted for individual ReHo
25
26 maps rather than during data preprocessing. Finally, nuisance signals (including Friston 24-
27
28 head motion parameters, the white matter, and CSF) will be extracted and regressed out from
29
30 the data to reduce the residual effects of nonneuronal factors. For the amplitude of low
31
32 frequency fluctuation (ALFF) analysis⁵⁷, the time series of each voxel will be transformed into
33
34 the frequency domain using a fast Fourier transform. The square root of the power spectrum
35
36 will be calculated and averaged across 0.01-0.08 Hz. This averaged square root will be taken
37
38 as the ALFF value for this voxel. For the ReHo analysis⁵⁸, Kendall's coefficient of concordance
39
40 (KCC) will be computed on the ranked time series of a given voxel with its 26 nearest
41
42 neighbours. The resultant KCC will be taken as the ReHo values. The generated ALFF and
43
44 ReHo images will be used for statistical analysis.

45
46 Network analysis. We will construct a structural cortical network based on grey matter
47
48 volumes.⁵⁹ The nodes will be defined as brain regions corresponding to automated anatomic
49
50 labelling (AAL) areas. The structural connections will be defined as statistical correlations
51
52 between pairs of average grey matter volumes in our study. A structural connection will be
53
54 considered to exist if the correlation coefficient is statistically significant. Before the correlation
55
56 analysis, the effects of age, sex and total grey matter volume on the grey matter volume of
57
58 regions will be adjusted. We will calculate Pearson correlation coefficients across individuals
59
60 between the average grey matter of every pair of regions, and then an interregional correlation
matrix will be obtained for every individual. We will construct a white matter network based

1
2
3
4 on fibre number. The network nodes will be defined as the 90 regions of interest corresponding
5 to the AAL template. The weight of the network edge will be defined as the number of
6 connected fibres with two regions. The fibre number will be calculated through diffusion tensor
7 imaging tractography as reported in our previous study.⁶⁰ To avoid spurious connections, a
8 minimum threshold of fibre number (weight of the edge=10) will be used. We will construct a
9 functional network based on the average time sequence. The network nodes will be defined as
10 the 90 regions of interest corresponding to the AAL template. The network edge will be defined
11 as the partial correlation coefficients between the average time sequence of two regions, and
12 we will obtain an incidence matrix. Non-significant correlations will be excluded. The network
13 analyses will be performed with the GRETNA toolbox (<http://www.nitrc.org/projects/gretna/>).⁶¹ The 'rich-club coefficient' is defined as the density of connections between rich-club
14 nodes and rich-club regions in our study will be defined the top 13 brain regions with the highest
15 degree as reported in our previous study.⁶² A module is defined as a subset of nodes connected
16 to the other nodes in the same module other than those outside the module.⁶³ We plan to use
17 Newman's metric to measure the modularity⁶⁴ and maximize the modularity parameter Q by
18 the algorithm proposed by Clauset et al.⁶⁵ The two parameters will be calculated for the
19 structural cortical network, white matter network and functional network constructed for each
20 individual. The values of the two measures will be calculated for every individual and used in
21 the model construction.

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41 T-fMRI data analysis. We will use SPM12 to process and analyse the t-fMRI data. The first
42 10 volumes will be discarded due to unsteady magnetization. First, the functional images from
43 each run will be realigned. The structural image will then be coregistered to the first scan in the
44 functional image, and the resulting coregistered structural image will be normalized to MNI
45 152 standard space. Finally, these spatially normalized functional images will be smoothed
46 (Gaussian kernel with an 8 mm FWHM).
47
48
49
50
51

52 53 54 **Statistical analysis**

55 56 **Baseline comparison between SCD convertors and SCD non-convertors**

57
58 All data (demographic information, clinical data, risk factors, neuropsychologic tests, blood
59 and urine biomarkers, multimodal MRI biomarkers, glucose mentalism, and amyloid deposition)
60

1
2
3
4 will be described. The Shapiro-Wilk test and Q-Q plots will be used to confirm the normality.
5
6 All normally distributed continuous variables will be reported as the mean \pm SD. A comparison
7
8 of the baseline between SCD convertors and SCD non-convertors will be performed with a
9
10 two-sample t-test for continuous variables and a chi-squared test for categorical variables.
11
12 Dunnett's multiple comparison tests will be performed for comparison.

13
14 Statistical analyses of t-fMRI data will be subjected to a general linear model analysis. The
15
16 MMN condition will serve as the predictor of interest and will be modelled with a boxcar
17
18 function convolved with the canonical haemodynamic response function; the Control condition
19
20 will serve as a baseline. The beta estimates from the individual general linear models enter a
21
22 second level random effects analysis. Contrast maps will be created by applying paired t-tests
23
24 comparing the MMN versus control condition for each group separately as well as a two-sample
25
26 t-test for the between-groups comparison. Activation maps will be corrected ($P < 0.001$) by the
27
28 false discovery rate approach implemented in SPM.

29 **Longitudinal patterns in SCD convertors**

30
31 The longitudinal analysis in neuropsychological, plasma, urine and MRI variables in SCD-
32
33 convertors will be assessed. We will use the general linear mixed effects model to estimate the
34
35 individual's change in each variable.

36 **Statistical prediction models**

37
38 We will use the competing risk regression model to detect the association between possible risk
39
40 factors and endpoint. The endpoint event of our study is converting to MCI. Death before
41
42 conversion to MCI is considered a competing risk in our study. The time to event is the date
43
44 difference between the baseline neuropsychological tests and the date at which the MCI or
45
46 dementia is first diagnosed.

47
48 Independent variables are listed in table 3, including features of baseline clinical
49
50 characteristics, blood, urine, MRI and PET biomarkers. Considering the overfitting effect when
51
52 establishing the model, the least absolute shrinkage and selection operator (LASSO) model with
53
54 penalty parameter tuning will be used for variable screening. It is a data mining method for
55
56 shrinkage estimation and dimensionality reduction, overcoming processing difficulties caused by
57
58 high-dimensional data, and estimating the parameters more accurately. Then, we will perform the
59
60 sub-distribution hazard function model, which could evaluate hazards for the endpoint (MCI or

dementia) and competing (death) events, to establish the final multivariate models. Ten-fold cross-validation is used to perform internal verification of the established models. The optimism-corrected C-statistics will be used to evaluate the performance of risk prediction models.

To better clarify the relationship between possible risk factors and endpoint events, some confounding factors will be adjusted. Four models will be established in our study. Model 1 will simply take demographic data, lifestyle, clinical assessment, neuropsychological assessments, and SCD report into account. Model 2 will add the ApoE genotype, plasma A β , and urine AD7c-NTP on the basis of model 1. Model 3 will take neuroimaging data into account on the basis of model 2 and model 4 will include amyloid-PET and FDG-PET on the basis of model 3.

The hazard ratio (HRs) with 95% confidence intervals are determined. A two-sided $p < 0.05$ is defined as statistical significance. All statistical tests were performed using R statistical software. The "glmnet" package will be used for the LASSO model analysis, and the "cmprsk" package will be performed for the sub-distribution hazard function model.

Table 3 independent variable list

Types	
Demographic data	age; education level; family history of dementia; socioeconomic information
Lifestyle	nicotine and alcohol use; sleep quality (PSQI, RBDSQ, ESS); nutrition style
Clinical assessment	vascular risk factors (hypertension, hyperlipemia, diabetes, coronary heart disease, Fazekas score); medial temporal lobe atrophy scale; HAMA; HAMD; GDS
Neuropsychological assessment	AVLT-D; AVLT-R; STT-A; STT-B; BNT; AFT
SCD report	onset time; comparison with others; SCD-Q9; Ecog; consistency of SCD; inform report
Blood tests	ApoE genotype; Plasma β -amyloid
Urine tests	level of AD7c-NTP
MRI data	cortical thickness; grey matter volume; FA; MD; RD; AxD; ALFF; ReHo; network characteristic (rich-club coefficient, modality); MMN-related haemodynamic

responses

PET data

global SUVR of FDG-PET and A β -PET

HAMA, the Hamilton Anxiety Scale; HAMD, the Hamilton Depression Scale; GDS, Geriatric Depression Scale; AVLT, Auditory Verbal Learning Test; STT, Shape Trails Test; BNT, Boston naming test; AFT, animal fluency test; SCD, subjective cognitive decline; FA, fractional anisotropy; MD, mean diffusivity; RD, radial diffusivity; AxD, axial diffusivity; ALFF, amplitude of low-frequency fluctuations; ReHo: regional homogeneity; SUVR, standardized uptake volume ratios; MMN: mismatch negativity

DISCUSSION

The current study evaluates the characteristics of SCD patients presenting cognitive decline within five years. Furthermore, we will construct risk forecast models based on different combinations of potential predictors to achieve early diagnosis in the preclinical stage of AD.

Considering the long preclinical stage of AD and compensated cognitive function in the SCD stage, the application of a refined SCD approach as an enrichment strategy for clinical trials focusing on preclinical AD shows great promise. SILCODE is a longitudinal study, and we will focus on features of SCD converters with multi-perspective analysis. In particular, we would like to establish an integrated diagnostic system for the early detection and prediction of SCD progressing at the individual level. We aim to provide scientific evidence for a more effective diagnosis of SCD due to AD and explore the underlying mechanism.

In this project, plasma A β , urine AD7c-NTP, and multimodal MRI will also be included in the predicting models. Plasma and urine biomarkers are non-invasive and feasible in clinical practice. Previous studies have found their diagnostic efficiency in MCI and dementia,^{46 66} but in SCD individuals, there are few pieces of evidence. Therefore, this project also focuses on new biomarkers and tries to identify their usage in the clinical scene. Additionally, through this project, we would like to reveal the longitudinal patterns of involved clinical and MRI biomarkers, especially the temporal sequences, which may provide a basis for us to understand the changes during disease progression.

The stage model theory proposes that human memory can be divided into three stages: sensory memory, short-term memory, and long-term memory.⁶⁷ The MMN has been proposed as an objective measure of the existence of auditory (visual, somatosensory) sensory memory traces.⁶⁸ Previous studies have suggested that MMN may have the potential to measure the age-

1
2
3
4 related changes⁴⁷ or improve the diagnostic value for the early diagnosis of AD.⁶⁹ Although
5 many more SCD studies have concentrated on short-term memory and long-term memory,^{18 70}
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

71 there are very few published studies on the sensory memory stage. SILCODE will investigate the changes in the initial memory stage in the SCD population and the predictive value of somatosensory MMN for disease progression in an exploratory way.

Finally, cultural factors were found to impact SCD by a cross-cultural comparison between the US and China,²¹ which indicates the need for SCD research in China. SILCODE is a longitudinal study in China, and the implementation of SILCODE would provide characteristics of SCD in China, which contribute to the harmonization of the SCD concept across cultural borders.

Author contributions

Xuanyu Li and Xiaoni Wang are joint first authors. Xuanyu Li and Xiaoni Wang are responsible for the implementation of the trial and manuscript draft and revision. Li Su is responsible for the design and implementation of imaging data analysis. Xiaochen Hu is responsible for the design of SCD and clinical assessments. Ying Han is responsible for the study design, implementation of the trial, manuscript draft and revision, and funding. All authors contributed to the drafting of the manuscript and approved the final manuscript.

Acknowledgements

The authors would like to thank Kun Yang for helping them to revise the statistical section of the manuscript. The authors would like to thank the participants of this study and patient advisers for their support.

Funding

This work was supported by The National Key Research and Development Program of China (2016YFC1306300), National Natural Science Foundation of China (Grant 61633018, 81801052, 81430037), Beijing Nature Science Foundation (7161009), Beijing Municipal Commission of Health and Family Planning (PXM2019_026283_000002), Alzheimer's Research UK (ARUK-SRF2017B-1), Addenbrooke's Charitable Trust, Alzheimer's Society

and The Lewy Body Society.

Competing interests

None declared.

Patient consent

All participation is based on written informed consent and the participants will be able to withdraw from the study at any time.

Ethics approval

Ethical approval of this has been obtained from the medical research ethics committee and institutional review board of the Xuanwu Hospital, Capital Medical University (ID: [2017]046).

Data sharing statement

Individual participant data that underlie future results published will not be publicly available but will be available from our laboratory after deidentification. Proposals for access should be sent to hanying@xwh.ccmu.edu.cn. The date will be the beginning 9 months and ending 36 months following future article publication with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis.

REFERENCES

1. Scheltens P, Blennow K, Breteler MM, *et al*. Alzheimer's disease. *Lancet* 2016;388(10043):505-17.
2. Jack CR, Jr., Knopman DS, Jagust WJ, *et al*. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* 2010;9(1):119-28.
3. Honig LS, Vellas B, Woodward M, *et al*. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. *N Engl J Med* 2018;378(4):321-30.
4. Doody RS, Thomas RG, Farlow M, *et al*. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med* 2014;370(4):311-21.
5. Dubois B, Hampel H, Feldman HH, *et al*. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* 2016;12(3):292-323.
6. Jessen F, Amariglio RE, van Boxtel M, *et al*. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement* 2014;10(6):844-52.
7. Molinuevo JL, Rabin LA, Amariglio R, *et al*. Implementation of subjective cognitive decline criteria

- 1
2
3 in research studies. *Alzheimers Dement* 2017;13(3):296-311.
- 4 8. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease.
5 *Annu Rev Clin Psychol* 2017;13:369-96.
- 6 9. Mitchell AJ, Beaumont H, Ferguson D, *et al.* Risk of dementia and mild cognitive impairment in older
7 people with subjective memory complaints: meta-analysis. *Acta Psychiatr Scand* 2014;130(6):439-51.
- 8 10. Dardenne S, Delrieu J, Sourdet S, *et al.* Memory Complaints and Cognitive Decline: Data from the
9 GUIDAGE Study1. *J Alzheimers Dis* 2017;60(4):1567-78.
- 10 11. Jessen F, Wolfsgruber S, Wiese B, *et al.* AD dementia risk in late MCI, in early MCI, and in
11 subjective
12 memory impairment. *Alzheimers Dement* 2014;10(1):76-83.
- 13 12. Buckley RF, Maruff P, Ames D, *et al.* Subjective memory decline predicts greater rates of clinical
14 progression in preclinical Alzheimer's disease. *Alzheimers Dement* 2016;12(7):796-804.
- 15 13. Hessen E, Eckerstrom M, Nordlund A, *et al.* Subjective Cognitive Impairment Is a Predominantly
16 Benign Condition in Memory Clinic Patients Followed for 6 Years: The Gothenburg-Oslo MCI Study.
17 *Dement Geriatr Cogn Dis Extra* 2017;7(1):1-14.
- 18 14. Vogel JW, Varga Dolezalova M, La Joie R, *et al.* Subjective cognitive decline and beta-amyloid
19 burden predict cognitive change in healthy elderly. *Neurology* 2017;89(19):2002-09.
- 20 15. Bessi V, Mazzeo S, Padiglioni S, *et al.* From Subjective Cognitive Decline to Alzheimer's Disease:
21 The Predictive Role of Neuropsychological Assessment, Personality Traits, and Cognitive Reserve. A 7-
22 Year Follow-Up Study. *J Alzheimers Dis* 2018;63(4):1523-35.
- 23 16. Fernandez-Blazquez MA, Avila-Villanueva M, Maestu F, *et al.* Specific Features of Subjective
24 Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment. *J Alzheimers Dis*
25 2016;52(1):271-81.
- 26 17. Wolfsgruber S, Kleineidam L, Wagner M, *et al.* Differential Risk of Incident Alzheimer's Disease
27 Dementia in Stable Versus Unstable Patterns of Subjective Cognitive Decline. *J Alzheimers Dis*
28 2016;54(3):1135-46.
- 29 18. Jessen F, Spottke A, Boecker H, *et al.* Design and first baseline data of the DZNE multicenter
30 observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*
31 2018;10(1):15.
- 32 19. Slot RER, Verfaillie SCJ, Overbeek JM, *et al.* Subjective Cognitive Impairment Cohort (SCIENCE):
33 study design and first results. *Alzheimers Res Ther* 2018;10(1):76.
- 34 20. Rodriguez-Gomez O, Sanabria A, Perez-Cordon A, *et al.* FACEHBI: A Prospective Study of Risk
35 Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study
36 Rationale and Research Protocols. *J Prev Alzheimers Dis* 2017;4(2):100-08.
- 37 21. Wu Q. Subjective cognitive impairment of older adults: a comparison between the US and China. *Int*
38 *J Methods Psychiatr Res* 2016;25(1):68-75.
- 39 22. Jackson JD, Rentz DM, Aghjayan SL, *et al.* Subjective cognitive concerns are associated with
40 objective memory performance in Caucasian but not African-American persons. *Age Ageing*
41 2017;46(6):988-93.
- 42 23. Hao L, Wang X, Zhang L, *et al.* Prevalence, Risk Factors, and Complaints Screening Tool
43 Exploration
44 of Subjective Cognitive Decline in a Large Cohort of the Chinese Population. *J Alzheimers Dis*
45 2017;60(2):371-88.
- 46 24. Rabin LA, Smart CM, Crane PK, *et al.* Subjective Cognitive Decline in Older Adults: An Overview
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- of Self-Report Measures Used Across 19 International Research Studies. *J Alzheimers Dis* 2015;48 Suppl 1:S63-86.
25. Perquin M, Diederich N, Pastore J, *et al.* Prevalence of Dementia and Cognitive Complaints in the Context of High Cognitive Reserve: A Population-Based Study. *PLoS One* 2015;10(9):e0138818.
26. Gifford KA, Liu D, Romano R, 3rd, *et al.* Development of a subjective cognitive decline questionnaire using item response theory: a pilot study. *Alzheimers Dement (Amst)* 2015;1(4):429-39.
27. Tomaszewski Farias S, Mungas D, Harvey DJ, *et al.* The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales. *Alzheimers Dement* 2011;7(6):593-601.
28. Chen KL, Xu Y, Chu AQ, *et al.* Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment. *J Am Geriatr Soc* 2016;64(12):e285-e90.
29. Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. *Control Clin Trials* 2000;21(6):552-60.
30. Licher S, Leening MJG, Yilmaz P, *et al.* Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies. *Am J Psychiatry* 2018:appiajp201818050566.
31. Pinto TCC, Machado L, Bulgacov TM, *et al.* Influence of Age and Education on the Performance of Elderly in the Brazilian Version of the Montreal Cognitive Assessment Battery. *Dement Geriatr Cogn Disord* 2018;45(5-6):290-99.
32. Bondi MW, Edmonds EC, Jak AJ, *et al.* Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. *J Alzheimers Dis* 2014;42(1):275-89.
33. Zhao Q, Lv Y, Zhou Y, *et al.* Short-term delayed recall of auditory verbal learning test is equivalent to long-term delayed recall for identifying amnesic mild cognitive impairment. *PLoS One* 2012;7(12):e51157.
34. Guo Q, Hong Z, Shi W, *et al.* Boston naming test in Chinese elderly, patient with mild cognitive impairment and Alzheimer's dementia. *Chinese Mental Health Journal* 2006;20(2):81-84.
35. Guo Q, Jin L, Hong Z, *et al.* A Specific Phenomenon of Animal Fluency Test in Chinese Elderly. *Chinese Mental Health Journal* 2007;21(9):622-25.
36. Zhao Q, Guo Q, Li F, *et al.* The Shape Trail Test: application of a new variant of the Trail making test. *PLoS One* 2013;8(2):e57333.
37. McKhann GM, Knopman DS, Chertkow H, *et al.* The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7(3):263-9.
38. Bhome R, Huntley JD, Price G, *et al.* Clinical presentation and neuropsychological profiles of Functional Cognitive Disorder patients with and without co-morbid depression. *Cogn Neuropsychiatry* 2019:1-13.
39. Buckley R, Saling M, Ellis K, *et al.* Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. *Age Ageing* 2015;44(6):1012-9.
40. Buysse DJ, Reynolds CF, 3rd, Monk TH, *et al.* The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28(2):193-213.
41. Nomura T, Inoue Y, Kagimura T, *et al.* Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson's disease patients. *Sleep Med* 2011;12(7):711-3.

- 1
2
3 42. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14(6):540-5.
- 4
5
6 43. Guo QH, Zhou B, Zhao QH, *et al.* Memory and Executive Screening (MES): a brief cognitive test
7 for detecting mild cognitive impairment. *BMC Neurol* 2012;12:119.
- 8
9 44. Llado-Saz S, Atienza M, Cantero JL. Increased levels of plasma amyloid-beta are related to cortical
10 thinning and cognitive decline in cognitively normal elderly subjects. *Neurobiol Aging*
11 2015;36(10):2791-7.
- 12
13 45. Hanon O, Vidal JS, Lehmann S, *et al.* Plasma amyloid levels within the Alzheimer's process and
14 correlations with central biomarkers. *Alzheimers Dement* 2018;14(7):858-68.
- 15
16 46. Nakamura A, Kaneko N, Villemagne VL, *et al.* High performance plasma amyloid-beta biomarkers
17 for Alzheimer's disease. *Nature* 2018;554(7691):249-54.
- 18
19 47. Strommer JM, Tarkka IM, Astikainen P. Somatosensory mismatch response in young and elderly
20 adults. *Front Aging Neurosci* 2014;6:293.
- 21
22 48. Shinozaki N, Yabe H, Sutoh T, *et al.* Somatosensory automatic responses to deviant stimuli. *Brain*
23 *Res Cogn Brain Res* 1998;7(2):165-71.
- 24
25 49. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage* 2005;26(3):839-51.
- 26
27 50. Fischl B, van der Kouwe A, Destrieux C, *et al.* Automatically parcellating the human cerebral cortex.
28 *Cereb Cortex* 2004;14(1):11-22.
- 29
30 51. Smith SM, Jenkinson M, Woolrich MW, *et al.* Advances in functional and structural MR image
31 analysis and implementation as FSL. *Neuroimage* 2004;23 Suppl 1:S208-19.
- 32
33 52. Woolrich MW, Jbabdi S, Patenaude B, *et al.* Bayesian analysis of neuroimaging data in FSL.
34 *Neuroimage* 2009;45(1 Suppl):S173-86.
- 35
36 53. Smith SM. Fast robust automated brain extraction. *Hum Brain Mapp* 2002;17(3):143-55.
- 37
38 54. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophys J*
39 1994;66(1):259-67.
- 40
41 55. Smith SM, Jenkinson M, Johansen-Berg H, *et al.* Tract-based spatial statistics: voxelwise analysis of
42 multi-subject diffusion data. *Neuroimage* 2006;31(4):1487-505.
- 43
44 56. Chao-Gan Y, Yu-Feng Z. DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-
45 State fMRI. *Front Syst Neurosci* 2010;4:13.
- 46
47 57. Zang YF, He Y, Zhu CZ, *et al.* Altered baseline brain activity in children with ADHD revealed by
48 resting-state functional MRI. *Brain Dev* 2007;29(2):83-91.
- 49
50 58. Zang Y, Jiang T, Lu Y, *et al.* Regional homogeneity approach to fMRI data analysis. *Neuroimage*
51 2004;22(1):394-400.
- 52
53 59. Yao Z, Zhang Y, Lin L, *et al.* Abnormal cortical networks in mild cognitive impairment and
54 Alzheimer's disease. *PLoS Comput Biol* 2010;6(11):e1001006.
- 55
56 60. Shu N, Wang X, Bi Q, *et al.* Disrupted Topologic Efficiency of White Matter Structural Connectome
57 in Individuals with Subjective Cognitive Decline. *Radiology* 2018;286(1):229-38.
- 58
59 61. Wang J, Wang X, Xia M, *et al.* GREYNA: a graph theoretical network analysis toolbox for imaging
60 connectomics. *Front Hum Neurosci* 2015;9:386.
62. Yan T, Wang W, Yang L, *et al.* Rich club disturbances of the human connectome from subjective
cognitive decline to Alzheimer's disease. *Theranostics* 2018;8(12):3237-55.
63. Radicchi F, Castellano C, Cecconi F, *et al.* Defining and identifying communities in networks. *Proc Natl Acad Sci U S A* 2004;101(9):2658-63.
64. Newman ME. Fast algorithm for detecting community structure in networks. *Phys Rev E Stat Nonlin*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Soft Matter Phys 2004;69(6 Pt 2):066133.

65. Clauset A, Newman ME, Moore C. Finding community structure in very large networks. *Phys Rev E*

Stat Nonlin Soft Matter Phys 2004;70(6 Pt 2):066111.

66. Zhang J, Zhang CH, Li RJ, *et al.* Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: a systematic review and meta-analysis. *J Alzheimers Dis* 2014;40(1):153-9.

67. McGaugh JL. Time-dependent processes in memory storage. *Science* 1966;153(3742):1351-8.

68. Naatanen R. Mismatch negativity: clinical research and possible applications. *Int J Psychophysiol* 2003;48(2):179-88.

69. Papaliagkas VT, Anogianakis G, Tsolaki MN, *et al.* Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels. *Dement Geriatr Cogn Disord* 2009;28(1):30-5.

70. Erk S, Spottke A, Meisen A, *et al.* Evidence of neuronal compensation during episodic memory in subjective memory impairment. *Arch Gen Psychiatry* 2011;68(8):845-52.

71. Rodda JE, Dannhauser TM, Cutinha DJ, *et al.* Subjective cognitive impairment: increased prefrontal cortex activation compared to controls during an encoding task. *Int J Geriatr Psychiatry* 2009;24(8):865-74.

Figure legend

Figure 1 Flow chart of SILCODE. SCD, subjective cognitive decline; fMRI, functional MRI; FDG-PET, fludesoxyglucose positron emission tomography; A β -PET, β -amyloid positron emission tomography; MoCA: Montreal Cognitive Assessment-basic

For peer review only




Figure 1 Flow chart of SILCODE. SCD, subjective cognitive decline; fMRI, functional MRI; FDG-PET, fluorodesoxyglucose positron emission tomography; Aβ-PET, β-amyloid positron emission tomography; MoCA: Montreal Cognitive Assessment-basic

90x90mm (300 x 300 DPI)